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Adam Christopher Riegel, B.A.
Supervisory Professor: Tinsu Pan, Ph.D.

Purpose: Respiratory motion causes substantial uncertainty in radiotherapy treatment
planning. Four-dimensional computed tomography (4D-CT) is a useful tool to image tumor
motion during normal respiration. Treatment margins can be reduced by targeting the
motion path of the tumor. The expense and complexity of 4D-CT, however, may be costprohibitive at some facilities. We developed an image processing technique to produce
images from cine CT that contain significant motion information without 4D-CT. The
purpose of this work was to compare cine CT and 4D-CT for the purposes of target
delineation and dose calculation, and to explore the role of PET in target delineation of lung
cancer.
Methods: To determine whether cine CT could substitute 4D-CT for small mobile lung
tumors, we compared target volumes delineated by a physician on cine CT and 4D-CT for 27
tumors with intrafractional motion greater than 1 cm. We assessed dose calculation by
comparing dose distributions calculated on respiratory-averaged cine CT and respiratoryaveraged 4D-CT using the gamma index. A threshold-based PET segmentation model of
size, motion, and source-to-background was developed from phantom scans and validated
with 24 lung tumors. Finally, feasibility of integrating cine CT and PET for contouring was
assessed on a small group of larger tumors.
Results: Cine CT to 4D-CT target volume ratios were (1.05±0.14) and (0.97±0.13) for highcontrast and low-contrast tumors respectively which was within intraobserver variation.
Dose distributions on cine CT produced good agreement (< 2%/1 mm) with 4D-CT for 71 of
73 patients. The segmentation model fit the phantom data with R2 = 0.96 and produced
v

PET target volumes that matched CT better than 6 published methods (-5.15%). Application
of the model to more complex tumors produced mixed results and further research is
necessary to adequately integrate PET and cine CT for delineation.
Conclusions: Cine CT can be used for target delineation of small mobile lesions with
minimal differences to 4D-CT. PET, utilizing the segmentation model, can provide additional
contrast. Additional research is required to assess the efficacy of complex tumor
delineation with cine CT and PET. Respiratory-averaged cine CT can substitute respiratoryaveraged 4D-CT for dose calculation with negligible differences.
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Chapter 1 INTRODUCTION AND BACKGROUND
1.1

Introduction
In 2009, an estimated 220,000 new cases of lung cancer were diagnosed, 87% of

which were non-small cell lung cancer (NSCLC). Deaths from lung cancer in 2009 were
projected to reach nearly 160,000, substantially higher than deaths attributed to prostate,
breast, and colorectal cancer combined. Lung cancer deaths account for 28% of all cancer
deaths in the United States (ACS, 2009). Radiation therapy is one important treatment
option for both early and later stage NSCLC. Shown to be an effective alternative to
surgical resection, radiation therapy can produce 5-year survival rates up to 27% for stage I
patients unfit or unwilling to undergo surgical resection (Dosoretz et al., 1992; Gauden et
al., 1995). Stage III patients are often treated with radiation therapy alone or a combination
of radiation therapy and chemotherapy, which, in terms of one-year survival, was
demonstrated to be statistically superior to radiation therapy alone (Sause et al., 1995).
The increasing use of radiation therapy in treatment of lung cancer has driven great
technological advances in the last decade, including intensity-modulated radiation therapy
(IMRT) and image-guided radiation therapy (IGRT). Treatment planning technology has,
necessarily, kept pace.
When patients are slated for radiation therapy, they first receive an imaging exam
on which the radiation treatment is planned. This exam, typically a computed tomography
(CT) exam, is performed in the treatment position and is often called a CT “simulation,”
referring to the fact that imaging geometry and patient setup mimic the geometry in the
treatment room. There are many uncertainties in treatment planning, but for lung cancer
patients, respiratory motion is especially significant. Typical helical CT scans can cause
significant image artifacts (Chen et al., 2004) which could lead to inaccurate targeting of the
tumor.
In 2004, a new imaging technology was introduced for CT simulation of lung cancer.
Four-dimensional computed tomography (4D-CT) enables physicists to capture a 3-D movie
of the patient’s respiratory pattern, thereby accurately representing the movement of the
1

tumor and allowing physicians to account for motion in the treatment plan (Keall et al.,
2004; Low et al., 2003; Pan et al., 2004; Rietzel et al., 2005). Typically, physicians will aim
radiation beams at the entire motion path of the tumor to ensure that the tumor stays
within the beam during the entire respiratory cycle.
A huge technological breakthrough, 4D-CT has become very popular in the last 5
years and has been adopted for CT simulation of lung cancer treatment at many centers
around the world including M. D. Anderson in Houston, Texas. The American Association of
Physicists in Medicine (AAPM) Task Group 76 highlights 4D-CT as a technique to effectively
assess tumor motion (Keall et al., 2006).
Parallel to the impressive advancement of medical technology in the last few
decades, however, is the steep increase in healthcare costs. The implementation of 4D-CT
is an example of one of these increases. The acquisition of 4D-CT imaging is a complex
process: Besides the scanner itself, additional hardware from a different vendor is required
to track the respiratory pattern of the patient. Such hardware may cost an additional
$75,000. In the General Electric implementation of 4D-CT, two additional pieces of
software are required to create 4D-CT images which, along with the proprietary workstation
on which the software runs, together may cost $300,000. After installation of the
technology, trained physicists and technicians must be present to ensure high-quality image
acquisition which, of course, will incur additional costs. Though such costs may be minimal
to an institution like M. D. Anderson or comparable university hospitals across the United
States, many smaller hospitals and clinics cannot afford such expenses after purchasing the
scanner itself.
Fortunately, there may be a way to make sophisticated imaging technology available
to the majority of hospitals with average resources. By manipulating CT images that are
used to create 4D-CT through re-sorting and image processing, we can create image sets
which contain significant motion information without additional hardware and minimal
software (Pan et al., 2006; Pan et al., 2007). These images could be used to plan radiation
therapy at a fraction of the cost of 4D-CT.
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The purpose of this dissertation was to determine if these alternative image sets,
generated by a process called “cine CT,” could, in conjunction with functional imaging such
as PET, be used for treatment simulation in place of 4D-CT. The work focused on
demonstrating equivalence of target delineation and dose calculation using cine CT and PET
compared with 4D-CT.

1.2

Background and Significance
Patients with NSCLC are staged according to the Revised International System for

Staging Lung Cancer which was adopted by the American Joint Committee on Cancer in
1997 (NCI, 2010). The system utilizes combinations of TNM classification to stratify patients
and is summarized in Table 1.1. “T” is generally determined by measuring tumor size. “N”
is found by assessing spread to regional lymph nodes. “M” is essentially a binary value
indicating whether or not the patient has distant metastasis. Because definitive radiation
therapy is particularly important for stage I and stage III NSCLC, the following investigations
are focused on these particular stages.

Table 1.1: Non-small cell lung cancer staging system based on TNM classification
IA
IB
IIA
IIB
IIIA
IIIB
IV
T1 N0 M0 T2 N0 M0 T1 N1 M0 T2 N1 M0 T1 N2 M0 T* N3 M0 T* N* M1
T3 N0 M0 T2 N2 M0 T4 N* M0
T3 N1 M0
T3 N2 M0
* = any numerical value
T = tumor stage
N = regional nodal status
M = distal metastasis

Computed tomography (CT) has revolutionized the treatment planning process for
radiation therapy, facilitating the transition from two-dimensional planning to threedimensional treatment simulation. CT, like conventional radiography, is a projection x-ray
modality. In current “third-generation” CT scanners, x-rays are produced in a fan beam by
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an x-ray tube rotating around the patient on a slip-ring gantry. The detector array rotates
with the gantry, capturing projections from different angles through the patient.
Projections are acquired at typical diagnostic energies such as 120 kVp, which provides a
mean energy of 60-70 kV for a polyenergetic x-ray spectrum. At these energies, the
photoelectric effect dominates total attenuation coefficient and produces useful contrast in
the x-ray projections. Transverse images are reconstructed using filtered backprojection.
Iterative reconstruction algorithms have been investigated (Marin et al., 2010), but are
computationally intensive. Graphics processing unit (GPU) reconstruction may expedite the
process (Xu et al., 2007). Obviously, scanner characteristics vary with manufacturer and
model, but many modern scanners are capable of multi-slice helical CT in which the
detector array consists of many individual detectors in the longitudinal direction (through
the scanner bore) that can be binned together to detect photons over a certain area. The
height of this binned area in the longitudinal direction defines the slice thickness. The
number of slices is defined by the number of data channels available. Helical acquisition is
performed by continuously moving the couch while the beam is on and acquiring data in a
“candy-stripe” pattern around the patient. Helical projection data is interpolated to form
projections at evenly spaced transverse slices (Bushberg, 2002).
The ability to localize tumors and define regions of interest (ROIs) in 3-D is a huge
advantage of CT simulation for radiation therapy. For lung cancer, however, respiratory
motion remains a huge source of uncertainty for radiotherapy planning, and increasing
treatment margins is undesirable due to additional normal tissue that will be irradiated in
the process. Furthermore, standard helical CT can induce severe artifacts when imaging
thoracic lesions due to respiratory motion (Chen et al., 2004). One proposed solution is
“slow” CT scanning, which uses a 4 second gantry rotation to capture breathing motion in
one rotation of the x-ray gantry (Lagerwaard et al., 2001). Although the AAPM Task Group
76 report advocates the use of slow scanning (Keall et al., 2006), significant image artifacts
can occur due to assumptions made in the filtered back-projection reconstruction process
that are violated by the slow scan technique (Bacharach, 2007).
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Four-dimensional computed tomography (4D-CT) overcomes these issues by
collecting multiple images at a single couch position, thereby capturing different phases of
the respiratory cycle (Keall et al., 2004; Low et al., 2003; Pan et al., 2004; Rietzel et al.,
2005). In the image-binning approach to 4D-CT reconstruction provided by one commercial
vendor (General Electric Healthcare, Waukesha, WI), image acquisition occurs in “cine
mode,” in which the couch is stationary and the gantry rotates around the patient
continuously acquiring data (Pan et al., 2004; Rietzel et al., 2005). Images are reconstructed
at pre-defined intervals and are sorted according to respiratory phase determined by a
respiratory surrogate, such as an external monitor of the location of the external patient
surface (Real-Time Positioning Management [RPM] system, Varian, Palo Alto, CA). Ten 3-D
image sets representing each phase of the respiratory cycle are formed (0% to 90%, where
0% represents end-inspiration and 50% represents end-expiration). The utility of 4D-CT was
recognized immediately in the radiation oncology community and several studies have
shown the use of 4D-CT in measuring lesion or organ motion (Brandner et al., 2006; Liu et
al., 2007) and implementing 4-D treatment planning (Kang et al., 2007; Rietzel et al., 2006;
Underberg et al., 2004).
One drawback to treatment planning with 4D-CT is the increased delineation
workload. Gross tumor volume (GTV) is defined in the International Commission on
Radiation Units and Measurements (ICRU) report 62 as “gross demonstrable extent and
location of malignant growth” (International Commission on Radiation Units and
Measurements., 1999) and is contoured by the radiation oncologist. For NSCLC, the GTV is
expanded with an isotropic margin (barring any anatomical boundaries to extension of gross
tumor) to the clinical target volume (CTV), which includes microscopic extension, and
expanded again to the internal target volume (ITV) which accounts for physiological motion
with the internal margin (International Commission on Radiation Units and Measurements.,
1999). One last margin for setup uncertainty expands the ITV to the planning target volume
(PTV). ICRU treatment volumes are illustrated in Figure 1.1 (left).
ICRU 62, however, was written in 1999, several years before 4D-CT was
commercially available and does not consider the consequences of 4-D imaging. For
5

example, ITV was originally intended as a generic expansion for physiological motion. Now,
it is possible to obtain patient
patient-specific motion parameters with 4D-CT,
CT, thereby making a
generic ITV expansion confusing and obsolete. Strictly interpreted from ICRU guidelines,
GTV should be contoured on each phase of 4D
4D-CT,
CT, which increases the delineation
delineat workload
ten-fold.

Figure 1.1:: Target volumes as described by ICRU 62 (left) and M. D. Anderson convention
(right). GTV = gross tumor volume. CTV = clinical target volume. ITV = internal target
volume. PTV = planning target volume. IGTV = internal gross tumor volume (dotted line).
ICTV = internal clinical target volume. EE = end
end-expiration. EI = end-inspiration.
inspiration. The M.
D. Anderson approach utilizes 4D
4D-CT to define a patient-specific motion path
characterized by IGTV.
Various techniques have been investigated to overcome this obstacle, including rigid
registration techniques (Ezhil et al., 2009; Liu et al., 2007
2007) and the use of maximum intensity
projection (MIP) (Bradley et al., 2006; Keall et al., 2006; Muirhead et al., 2008; Rietzel et al.,
2006; Rietzel et al., 2008; Underberg et al., 2005)
2005). The MIP is a single 3-D
D image set
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processed from 4D-CT data. Each voxel displays the maximum CT value it encountered
throughout the 10 phases of the respiratory cycle. Because of the substantial difference in
electron density between the tumor, which is similar to “soft tissue,” and the surrounding
lung parenchyma, which is typically about 1/4 the density of soft tissue (Khan, 2003), the
MIP, in essence, displays the “motion envelope” of the tumor, a record of everywhere the
tumor moves over a respiratory cycle.
Because radiation oncologists typically target the motion envelope of the tumor for
radiation therapy (treatment delivery technology is not yet sophisticated enough to reliably
track the tumor during treatment, though this is an active area of research (Suh et al.,
2009)), various institutions have independently modified ICRU target volume definitions to
incorporate 4-D imaging into the simulation procedure. At M. D. Anderson, the internal
gross tumor volume or “IGTV” has been defined as the motion envelope of the gross tumor
which is expanded for microscopic disease to the internal clinical target volume (ICTV),
illustrated in Figure 1.1 (right). A recent study found that IGTV contoured on MIP was
significantly larger than GTV contoured on helical CT, which implies a more “inclusive”
method of GTV determination thus less chance of geographic miss (Bradley et al., 2006).
Several studies have shown that contouring IGTV with MIP produces volumes similar to the
union of 10 phase GTVs from 4D-CT (Park et al., 2009; Rietzel et al., 2005; Rietzel et al.,
2008; Underberg et al., 2005), suggesting that MIP could be used to define targets for
radiation therapy instead of all 10 phases of 4D-CT.
Similar image processing techniques can be applied to 4D-CT data to produce other
useful image sets, such as the minimum intensity projection (min-ip), which displays the
minimum voxel value instead of maximum voxel value, and the respiratory-averaged CT
(RACT), which is the arithmetic average of the 10 phases of 4D-CT. The RACT appears as a
motion-blurred CT image and can be used for dose calculation (Admiraal et al., 2008; GlideHurst et al., 2008) and attenuation correction of positron emission tomography (Chi et al.,
2007; Pan et al., 2005). Examples of end-inspiration and end-expiration phase images from
4D-CT, as well as MIP and RACT, are shown in Figure 1.2.
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Figure 1.2: (A)) maximum intensity projection and (B) respiratory-averaged
averaged CT from 4D-CT.
4D
End-expiration and end-inspiration,
inspiration, the extremes of respiratory motion, are shown in 4DCT phase images (C) 50% phase and (D) 0% phase.
Recently, a technique was developed to produce RACT directly from cine CT data for
the purpose of attenuation correction of diagnostic thoracic PET/CT for which 4D-CT is not
performed (Pan et al., 2006).. In this case, RACT is formed by averaging all the images at
each couch position (between 20
20-30 images, depending on user-defined
defined parameters)
instead of a 10-phase
phase subset as determined by 4D
4D-CT. The same principle can be applied to
MIP processing; instead
ad of taking the MIP of the 10 phases of 4D
4D-CT,
CT, one can take the MIP
of all images reconstructed from the cin
cine acquisition (Figure 1.3). In this work,
work the image
sets from which MIP and RACT are derived are denoted by a subscript. For example, MIP
processed from cine CT is “MIPcine.” The advantage of processing directly from cine CT is
that 4D-CT
CT is no longer required to form MIP which, according to tthe
he studies above, can be
used for target definition of the IGTV. This suggests that creating MIP directly from cine
cin CT
may be a way to bypass the complex and expensive 4D
4D-CT
CT process but still incorporate
substantial motion information into the treatment p
plan.
A significant drawback of MIP, however, is the lack of contrast when tumors are
located near structures of equal or greater density (Bradley et al., 2006; Muirhead et al.,
2008;
08; Rietzel et al., 2005; Rietzel et al., 2008; Underberg et al., 2005)
2005).. Consider, for
example, a tumor located just superior to the liver. The liver moves substantially during
respiratory motion and can “overwrite” the inferior motion envelope of the tumor, making
it nearly impossible to determine the inferior extent of the tumor’s motion (Figure
(
1.4).
Another example of this problem is a tumor aadjacent to the chest wall (Figure
Figure 1.5).
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4D-CT imaging versus raw cine CT imaging. MIP =
Figure 1.3:: Image processing of 4D
maximum intensity projection, RACT = respiration
respiration-averaged
averaged computed tomography.
tomography
Reproduced with permission from Riegel et al. (Riegel et al., 2009)
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Figure 1.4: Sagittal views of a moving lesion obscured by the liver. (A) MIP without
contour. (B) MIP with end-inspiration
inspiration tumor contour (orange). (C) End-inspiration
inspiration phase
with contour drawn for reference. Note that the inferior border of the tumor is nearly
impossible to delineate with the MIP alone.

Figure 1.5: Sagittal CT image of tumor near the chest wall. (left) Maximum intensity
projection. (right) Respiratory
Respiratory-averaged CT. Reproduced with permission from Riegel et
al. (Riegel et al., 2009)
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It is plausible, however, that additional image sets could be used to supplement
MIPcine and provide enough information for accurate target definition. Consider the
example of the tumor near the chest wall: The tumor is easily defined in the superior,
inferior, and anterior directions on the MIPcine image (Figure 1.5, left), but the contrast is
poor in the posterior direction. The RACTcine image, however, provides good contrast for
the posterior extent of the tumor due to a density gradient caused by motion blurring
(Figure 1.5, right). Used together, it is feasible that the MIPcine and RACTcine could be used
for IGTV delineation of small, highly mobile tumors (Pan et al., 2007). For larger, more
complicated tumors, however, it is likely that cine CT alone will not provide enough
information for IGTV delineation. This hypothesis is supported by a result publication by
Muirhead et al. in which target delineation on MIP4D-CT was compared with 4D-CT phase
imaging in patients stratified by lung cancer stage. The authors found that MIP could be
reliably substituted for 4D-CT in stage I lesions, but not stage II or III (Muirhead et al., 2008).
Lesion/normal tissue contrast may be enhanced by adding a second imaging
modality. The integration of fluorodeoxyglucose positron emission tomography (FDG-PET)
into the treatment planning process is another recent development in radiation oncology,
facilitated by the hardware fusion of PET/CT scanners. Several studies have analyzed the
impact of including PET data in GTV delineation for NSCLC and have yielded noteworthy
results, mostly due to the inclusion of lymph nodes and the exclusion of atelectasis
(Ashamalla et al., 2005; Bradley et al., 2004; Erdi et al., 2002; Nestle et al., 1999; van
Baardwijk et al., 2006).
PET imaging provides quantitative data regarding the metabolic behavior of the
patient. In that sense, it is a functional imaging modality, as opposed to CT which is a
structural imaging modality. To acquire a PET scan, a patient is injected with a radiotracer,
that is, a compound that follows metabolic pathways but has a radioactive isotope attached
to it. In almost all oncological PET imaging, the compound used is fluorodeoxyglucose
(FDG). FDG behaves like glucose (except with a radioactive 18F atom attached) and follows
the glycolytic pathway until it becomes phosphorylated by hexokinase and becomes
trapped in the cell. The 18F nucleus decays to 18O by positron (β+) decay. The ejected
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positron travels a certain distance (the “range” of the positron, which is unique to the
isotope and is related to the initial energy of the positron after decay) and undergoes
annihilation with an electron, emitting two 511 keV photons at approximately 180° from
each other. These photons are detected by a ring of detectors positioned around the
patient that discriminate detection events based on energy (a window around 511 keV) and
time. Each event is recorded as a line of response, which is placed in a sinogram and is
reconstructed using an iterative reconstruction technique such as maximum likelihood
expectation maximization (Lange et al., 1984; Shepp et al., 1972) or, more recently, ordered
subsets expectation maximization (OSEM) (Hudson et al., 1994).
One advantage of using PET images to delineate that GTV is the application of autosegmentation techniques. Currently, there is very little guidance on exactly how to
incorporate PET information into the delineation process, and, consequently, different
physicians can produce different GTVs (Riegel et al., 2006). Auto-segmentation would
standardize this process, thereby decreasing interobserver variation and simplifying the
delineation process.
Target volume delineation of lung cancer with PET/CT has been extensively reported
in the literature (Biehl et al., 2006; Black et al., 2004; Brambilla et al., 2008; Caldwell et al.,
2003; Davis et al., 2006; Drever et al., 2007; Erdi et al., 1997; Nestle et al., 2005; Okubo et
al., 2008; Park et al., 2008; Paulino et al., 2004), yet little consensus exists on exactly how to
use PET to define a GTV (Nestle et al., 2006). Some studies recommend using an absolute
SUV threshold such as 2.5 g/mL (Paulino et al., 2004), while others advocate a fixed
percentage threshold of maximum activity concentration or standardized uptake value
(SUV) (Erdi et al., 1997; Okubo et al., 2008). Biehl et al., however, have shown that a single
threshold for all lung lesions is inadequate and recommend thresholds varying from 15% of
maximum activity concentration for tumors greater than 5 cm and 42% of maximum activity
concentration for tumors less than 3 cm (Biehl et al., 2006). Black et al. derived a linear
relationship for optimal thresholds from phantom scans as a function of mean SUV, which
is, in turn, a function of background activity and target volume (Black et al., 2004).
Brambilla et al. found that both target size and source-to-background ratio were significant
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ors in determining appropriate activity concentration thresholds and recommended
factors
that both variables be included in automatic segmentation algorithms (Brambilla et al.,
2008). Van Baardwijk et al.,, by way of thresholds determined by Daisne et al. (Daisne et al.,
2003),, included both variables in their segmentation algorithm, applied the method to
patients, and found good correlation with pathological specimen
specimens (van Baardwijk et al.,
2007).

Figure 1.6: PET image of 37 mm diam
diameter
ter sphere moving at 0, 10, 20, and 30 mm
sinusoidal motion.
One significant variable that most of these studies ignore is motion. Because PET
acquisition occurs over several m
minutes
inutes to accumulate coincidence events, the effect of
respiratory motion on PET imaging is a blurring of the tumor: Activity is spread out over
voxels in the motion path of the tumor (Figure 1.6) which can lead to inaccurate
ccurate
quantification (Boucher et al., 2004) and exaggerated tumor geometry (Okubo et al., 2008).
2008)
The aforementioned
tioned segmentation studies focused either on stationary o
objects
bjects in a
phantom or moving objects in PET compared with a free
free-breathing
breathing or breath-hold
breath
CT.
Comparison with free-breathing
breathing CT will most likely be inaccurate due to the possibility
possib
of
motion artifacts (Chen et al., 2004)
2004), and comparison with breath-hold
hold CT, while accurate,
will be inappropriate because, typically, a breath
breath-hold
hold CT is not used for treatment planning
when 4D-CT is available. Recall that 4D
4D-CT
CT is used in radiation therapy planning of moving
lung lesions to define the IGTV, the motion envelope of the tumor.
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It seems logical, then, to compare PET to 4D-CT to determine an optimal
segmentation method. Caldwell et al. found that PET could indeed be used to determine
IGTV for radiation therapy planning but that, as a result of their moving phantom study,
conventional threshold values (acquired at rest) produced volumes that were too small.
They reduced the threshold to 15% of maximum activity concentration to adequately
capture what the authors called “ITV” (Caldwell et al., 2003). Similarly, Yaremko et al. found
that hot spheres moving in air required a reduced threshold (25%) to capture the IGTV
(Yaremko et al., 2005). To date, however, there have not been studies optimizing activity
concentration thresholds using 4D-CT as the reference for phantoms or patients, though
some of the aforementioned segmentation studies have called for just such an investigation
(Biehl et al., 2006; Okubo et al., 2008).
If a robust segmentation protocol could be developed for moving lung tumors, then
radiation oncologists could apply such a protocol to radiation therapy treatment planning
with the confidence that PET is providing accurate targeting information. Recall that the
main drawback with target delineation using MIPcine and RACTcine was the lack of contrast
for tumors with complicated structure. By using cine CT image sets and PET together
(utilizing the segmentation protocol), there may be enough information for target
delineation and treatment planning.
The purpose of this dissertation was to develop a treatment planning technique
using image sets processed from cine CT in conjunction with PET imaging as a substitute for
4D-CT. The work is split into 4 chapters: First, we examined the use of MIPcine and RACTcine
for the purpose of contouring stage I NSCLC; second, we examined the use of RACTcine for
dose calculation; third, we developed a threshold-based auto-segmentation model to
accurately contour moving lung tumors; finally, we assessed the feasibility of using cine CT
image sets and the PET auto-segmentation algorithm together to contour stage III NSCLC.
If successful, thoracic radiotherapy treatment planning with cine PET/CT may rival
conventional 4D-CT plans at a fraction of the cost, thereby enabling small, local treatment
centers to provide motion-encompassing treatment plans to lung cancer patients.
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1.3

Summary of Chapters

1.3.1 Chapter 2: Target Delineation of Stage I Non-Small Cell Lung Cancer with Cine
CT
Early-stage lung tumors are often small, well-defined, and can be very mobile. Our
first task was to use MIPcine and RACTcine to contour early stage lung cancer for group of
patients slated for stereotactic body radiation therapy (SBRT). The purpose was to
determine if target definition with MIPcine and RACTcine was similar to target definition with
4D-CT. Chapter 2 was split into 2 parts: The phantom study and the patient study.
Phantoms were used to assess differences between cine CT and 4D-CT in a controlled
environment and patients were used for clinical significance.
In the phantom study, a body phantom with 6 spheres was placed on a motion
platform and moved in an irregular respiratory pattern while cine CT was acquired. MIPcine
and MIP4D-CT were formed and auto-segmented in a treatment planning system for volume
comparison. In the patient study, cine CT images obtained during treatment simulation
were used to form MIPcine and RACTcine image sets. These image sets then were used
together to define IGTVs. Patients were included if tumor motion was greater than 1 cm.
Lesions were contoured first using MIPcine and RACTcine, then with MIP4D-CT along with 10phase image sets. Mean ratios of volume magnitude were compared with intraobserver
variation, the variation expected by a physician contouring the same region multiple times.
Mean shifts in centroid location were calculated, and volume overlap was assessed with the
normalized Dice similarity coefficient index.
The patient studies demonstrated that IGTV defined on cine imaging was similar to
or slightly larger than IGTV defined on 4D-CT. Phantom studies of irregular motion
confirmed that IGTV defined on cine CT imaging was indeed larger and therefore more
accurately captured the maximum motion extent of irregular respiration.
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1.3.2 Chapter 3: Dose Calculation with Cine Respiratory-Averaged CT
Dose calculation for thoracic radiotherapy is commonly performed on a freebreathing helical CT despite artifacts caused by respiratory motion. Some centers now use
RACT4D-CT, the pixel-by-pixel average of the 10 phases of 4D-CT, for dose calculation.
RACTcine, however, may be a means to incorporate motion information into dose calculation
without performing 4D-CT. The purpose of this chapter was to determine if RACTcine could
be substituted for RACT4D-CT for the purposes of dose calculation, and if increasing the cine
duration can decrease differences between the dose distributions. Cine CT data and
corresponding 4D-CT simulations for 23 patients with at least 2 breathing cycles per cine
duration were retrieved. RACT was generated four ways: (1) from 10 phases of 4D-CT, (2)
from 1 breathing cycle of images, (3) from 1.5 breathing cycles of images, and (4) from 2
breathing cycles of images. The clinical treatment plan was transferred to each RACT and
dose was recalculated. Planar dose distributions were exported on orthogonal planes
through the isocenter (coronal, sagittal, and transverse orientations). The resulting dose
distributions were compared using the gamma (γ) index within the planning target volume
(PTV). Failure criteria were set to 2%/1mm. A follow-up study with 50 additional lung
cancer patients was performed to increase sample size. The same dose recalculation and
analysis was performed.
In the primary patient group, 22 of 23 patients had 100% of points within the PTV
pass γ criteria. The average maximum and mean γ indices were very low (well below 1),
indicating good agreement between dose distributions. Increasing the cine duration
generally increased the dose agreement. In the follow-up study, 49 of 50 patients had 100%
of points within the PTV pass the γ criteria. The average maximum and mean γ indices were
again well below 1, indicating good agreement. Dose calculation on RACTcine is negligibly
different from dose calculation on RACT4D-CT. Differences can be decreased further by
increasing the cine duration of the cine CT scan.
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1.3.3 Chapter 4: Segmentation of Moving Targets with PET/CT: Correlation of
Thresholds with Lesion Size, Motion Extent, and Source-to-Background Ratio
Several studies consider size and source-to-background ratio (SBR) in their
automatic segmentation methods but neglect respiratory motion. The purpose of this
chapter was to model the relationship between optimal activity concentration threshold,
tumor volume, motion extent, and SBR using multiple regression techniques. An extensive
series of phantom scans simulating tumors of varying size, SBR, and motion amplitudes was
performed. Regions of interest delineated on PET were compared with the “motion
envelope” of the moving sphere defined on cine CT.
A NEMA IEC thorax phantom containing 6 spheres of inner diameters 10, 13, 17, 22,
28, 37 mm was filled to 6 SBRs (5:1, 10:1, 15:1, 20:1, 30:1, 50:1) and was placed on a motion
platform and moved sinusoidally at 0, 5, 10, 15, 20, 25, 30 mm amplitudes (252
combinations of experimental parameters). PET images were acquired for 18 minutes and
split into three 6-minute acquisitions to assess reproducibility. The spheres (blurred on PET
images due to motion) were segmented at 1% intervals of maximum activity concentration.
The optimal threshold was determined by comparing threshold volume surfaces with a
reference volume surface defined on cine CT. Optimal activity concentration thresholds
were normalized to background and multiple regression was used to determine the
relationship between optimal threshold, volume, motion, and SBR. Standardized regression
coefficients were used to assess the relative influence of each variable.
The model was validated using patient data. PET and 4D-CT were performed in the
same imaging session for 23 patients (24 tumors) for radiation therapy planning. IGTVs
were segmented on MIPcine and activity concentration thresholds which best matched were
determined. IGTVs were delineated on PET imaging using our segmentation model and
following methods for comparison: 15%, 35%, and 42% of maximum activity concentration,
SUV of 2.5 g/mL, 15% of mean activity concentration plus background, a linear function of
mean SUV, and our motion-inclusive model derived from phantom scans. Threshold values
produced from each method were correlated with best-matched threshold values. PET
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target volumes were geometrically compared to cine CT target volumes using volume
magnitude and surface separation.
The resulting model and coefficients provided a functional form that fit the phantom
data with an adjusted R2 = 0.96. The most significant contributor to threshold level was SBR.
Our technique yielded threshold values well-correlated with measured optimal thresholds
(slope = 0.8991, R2 = 0.8577) and produced PET to CT volume differences smaller than the 6
other methods (-5.15%) and surface separation smaller than 5 other methods (1.6 mm).
IGTVs at 35% and 42% maximum activity concentration substantially underestimated the
motion envelope of the tumor in most patients.
1.3.4 Chapter 5: Target Delineation of Stage III Non-Small Cell Lung Cancer with Cine
PET/CT
The segmentation model developed in Chapter 4 was applied to 5 patients with
NSCLC: 4 patients with stage III disease, 1 with stage I disease. Feasibility of using the PET
segmentation model in conjunction with MIPcine was assessed qualitatively. The
segmentation model produced reasonable target volumes for 3 of 5 patients. Tumors of 2
patients, however, were not delineated accurately. Further research is required for this
application of the segmentation model. Accounting for nodal involvement was not
investigated in this chapter but is critical for accurate segmentation of stage III NSCLC and
therefore should be explored in the future.
1.3.5 Chapters 6 and 7: Discussion and Conclusions
Results from Chapters 2, 3, 4, and 5 are discussed in the context of the cine PET/CT
workflow. Recommendations are made based on experimental results.
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Chapter 2 TARGET DELINEATION OF STAGE I NON-SMALL CELL LUNG CANCER WITH
CINE CT

2.1

Introduction
Radiation therapy is an important treatment option for stage I NSCLC. Though

surgery is still the standard of care, stereotactic body radiation therapy (SBRT) has been
shown to be as effective as resection for inoperable stage I NSCLC (Chang et al., 2007;
Timmerman et al., 2007) and multicenter clinical trials are underway to assess the efficacy
of SBRT in operable NSCLC. In contrast with conventionally-fractionated radiation therapy,
SBRT utilizes a hypofractionated approach. At M. D. Anderson, for example, the tumor
receives 60 Gy in 4 fractions, or 15 Gy per fraction, as compared with 66 Gy in 2 Gy fractions
in conventional radiation therapy. Beyond the convenience of four-fraction treatment for
the patient, the combination of hypofractionation, multiple fields, and image guidance
allows higher ablative doses to be delivered to the tumor while keeping normal tissue
toxicity at an acceptable level (Timmerman et al., 2007). High doses per fraction, however,
mean that accuracy becomes even more critical to avoid geometric miss.
To account for respiratory motion in the SBRT treatment plan, a 4D-CT exam is used
to image 10 phases of the patient’s respiratory cycle and target the motion path of the
tumor. Earlier, the complexity and cost of 4D-CT was briefly described. The 4D-CT imaging
process is explained here in more detail to highlight the differences between the
conventional 4D-CT approach and the cine CT approach.
The scanner setup is slightly different for 4D-CT simulation than for standard helical
CT simulation. In addition to the flat table-top and wing board, the patient’s respiration is
monitored and recorded (Real-Time Positioning Management, Varian, Palo Alto, CA). The
system consists of an infrared camera and a CCD detector docked on the end of the couch
and a small plastic box with two reflective markers which is placed on the patient’s
abdomen (Figure 2.1). The box acts as the surrogate for the patient’s respiratory pattern,
moving up and down with each inhalation and exhalation of breath.
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For GE CT scanners, images are acquired in “cine” mode in which the couch is
stationary, and the x-ray
ray tube rotates around the patient multiple times acquiring a
continuous stream of projection data. After enough da
data
ta has been collected, the beam is
turned off and the couch moves to the next bed position and acquisition begins again.

Figure 2.1:: Respiratory surrogate setup for 4D
4D-CT acquisition. The infrared camera tracks
the movement of the infrared reflector on the patient’s abdomen to record the
respiratory motion trace.
Several user paramet
parameters
ers define the cine acquisition. Gantry rotation “speed”
(typically quoted as the gantry rotation p
period) typically runs between 0.3 s and 1 s
depending on the scanner model. The cine duration (CD) is the amount of time projections
are acquired at each bed position, in other words, the “beam on” time. Typically, the CD is
chosen to reflect the average breathing period of the patient plus one second to ensure
that a complete set of project
projectionss exists for reconstruction at the beginning and end of cine
acquisition (Pan et al., 2004).. Because cine data is a long stream of projection data, the user
must define how the stream will be split into reconstructed images (i.e. which projections
belong to which reconstruction). The cine interval (CI) defines the temporal separation
between adjacent image reconstructions. The cine interval need not be limited by gantry
rotation speed (one projection per one gantry rotation); projections can be used in multiple
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image reconstructions to produce finer temporal sampling. In clinical practice, this is often
the case. Typical CI’s range from 0.2 to 0.3 s with a gantry speed of 0.5 s. When the CI is
finer than the gantry rotation speed, projection data is used redundantly in adjacent
images. The trade-off to finer temporal sampling, however, is an increased number of
images. Typically, 10-30 images are reconstructed per cine duration. To scan 20-25 cm of
anatomy with 2.5 mm slice thickness, 2400-3000 images are generated. Currently, the
number of images generated from cine acquisition is limited to 3000 due to reconstruction
time and storage limitations.
This large set of images is commonly referred to as “cine CT.” Each image captures a
distinct moment in time and space like a frame in a movie reel. It is at this point where our
experimental method detours from the conventional 4D-CT technique. The experimental
method will be discussed shortly.
Because of the time required to move the couch from one position to the next, the
series of cine CT images captures a different starting phase of the breathing cycle each time.
This effect is demonstrated in Figure 1.3. Reconstructing 3-D image sets based on image
number, then, would be non-sensical (image 1 of couch position 1 does not match the same
part of the respiratory cycle of image 1 of couch position 2.) Irregular respiration further
complicates this problem. The cine CT images must therefore be sorted into different
respiratory states and then combined to form 3-D image sets for each respiratory state.
The respiratory state is provided by the trace recorded by the respiratory monitoring
device. Typically, the respiratory cycle is divided into 10 equidistant phase-bins from one
inspiration to the next. Proprietary software is used to match cine CT images with their
appropriate phase by examining the midscan time of each cine CT image and comparing it
with the respiratory trace. The result is 10 3-D image sets, each one representing a
different phase of respiration (hence the term “4D-CT”).
As described in section 1.2, contouring the tumor on 4D-CT is time-consuming and
labor-intensive. The maximum intensity projection (MIP) is often used to display the
“motion envelope” of the tumor in a single image set. Several studies have shown that
target delineation on MIP is similar to target delineation on 4D-CT (Rietzel et al., 2005;
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Rietzel et al., 2008; Underberg et al., 2005). Clinically, at M. D. Anderson, MIP4D-CT and 4DCT phase images are used together to define the tumor and its motion extent (Ezhil et al.,
2009).
Recall that our experimental method deviates from 4D-CT acquisition at the series of
cine CT images, just before the sorting into phase bins. We have developed software to
create MIP directly from the cine CT images, bypassing the sorting process of 4D-CT (Pan et
al., 2007). The differences between the 4D-CT approach to MIP and cine CT approach to
MIP are shown diagrammatically in Figure 1.3. As described in the background and
significance section, this could eliminate significant costs of 4D-CT simulation while still
providing useful motion information for planning purposes.

2.2

Purpose
In this chapter, we compared two methods of IGTV segmentation on highly mobile

early stage lung tumors: First, the conventional 4D-CT approach utilizing phase imaging
from 4D-CT and MIP processed from 4D-CT and second, the experimental “cine CT”
approach utilizing MIPcine and RACTcine. The goal of this chapter was to show that the
experimental method can produce target volumes similar to the conventional 4D-CT
method.

2.3

Methods

2.3.1 Phantom Study
Because 4D-CT is essentially a subset of cine CT, we anticipated that generating a
MIP from 10 phase image sets would yield a target volume different from a MIP generated
from all images captured during the cine duration (20-30 images) when the motion is
irregular, which is usually the case with patient scanning. The objective of the phantom
study was to show that MIPcine visualized the full extent of irregular motion more precisely
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than MIP4D-CT. In other words, we wanted to demonstrate that volumes segmented on
MIPcine were larger than those from MIP4D-CT.

Figure 2.2:: NEMA IEC thorax phantom (Data Spectrum, Chapel Hill, NC) placed on a
motion platform driven by a single-axis
axis stepper motor (Velmex Inc., Bloomfield, NY).
NY)
Note the RPM block placed on the phantom.
A body phantom made in accordance with National Electrical Manufacturers
Association (NEMA) and International Electrotechnical Commission (IEC) recommendations
was used (Data Spectrum, Chapel Hill, NC). The phantom contained 6 water-filled
water
spheres
was scanned using a cine CT protocol on a PET/CT scanner (Discovery
Discovery ST, General Electric
Healthcare, Waukesha, WI),, the CT portion of which is aan 8-slice scanner. The background
tank was filled with air. The phantom was placed on a platform and moved
d oneone
dimensionally, driven by a single
single-axis stepper motor
or (Velmex Inc., Bloomfield, NY).
NY)
Experimental setup is shown in Figure 2.2. The irregular motion (previously described in
Starkschall et al. (Starkschall et al., 2007)
2007))) was nearly sinusoidal with amplitude and
frequency respectively
ctively varying from 0.7 to 1.1 cm and 15 to 20 cycles per minute. The
following cine scan protocol was repeated 10 times on the moving phantom: 120 kV, 50
mA, 2.5
5 mm slice thickness, gantry rotation of 0.5 s, cine interval of 0.2 s, cine duration of
7.5 s (twice the average breathing cycle of the irregular patt
pattern
ern plus one gantry rotation).
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Images were reconstructed with filtered backprojection (Brooks et al., 1975) to a 512 by 512
image matrix with 50 cm field of view (FOV). MIP4D-CT and MIPcine were reconstructed.
Images were transferred to a commercial radiation treatment planning system
(Pinnacle3, version 7.6, Philips Medical Systems, Madison, WI) for contouring and a -700
Hounsfield unit (HU) threshold was used to segment IGTVs on MIPcine and MIP4D-CT image
sets (denoted IGTVcine and IGTV4D-CT respectively). Volume measurements were recorded
for each of the 6 spheres on the 10 scans, and a paired t-test was used to measure
statistically significant differences between the mean volume magnitudes of IGTV4D-CT and
IGTVcine.
2.3.2 Patient Study
We reviewed the radiation oncology patient database at M. D. Anderson to identify
patients with stage I NSCLC who had been treated with SBRT, received 4D-CT simulation,
and had tumor motion extent greater than 1 cm. Between January of 2005 and April of
2007, 26 patients (27 tumors) fit the criteria. The study protocol was DR07-0809, approved
by the institutional review board (IRB). We determined the extent of tumor motion by
visually assessing the displacement between extreme phases of the 4D-CT (usually 0% and
50%). Motion extent greater than 1 cm was included because this feature represents the
“worst case” scenario for motion artifact. According to Liu et al., approximately 10% of
stage I and stage III tumors move more than 1 cm (Liu et al., 2007). If target delineation on
cine CT is similar to 4D-CT for the larger motions, the method demonstrated in this study
could easily be applied to scenarios where motion is less severe.
Patients were divided into two groups: 12 patients were in the “high contrast”
group (13 tumors), with lesions in the middle of the lung parenchyma, and 14 were in the
“low contrast” group, with lesions adjacent to structures of equal or higher density.
Patients were separated in this fashion to reflect the concerns of previous studies that the
MIP does not provide enough contrast to determine the tumor edges when the target is
adjacent to dense structures (Rietzel et al., 2005; Underberg et al., 2005). Furthermore, we
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did not want the success of segmentation in the high-contrast cases to blur statistically
significant differences from the low-contrast cases.
In the course of 4D-CT simulation, each patient received a cine CT scan during which
the patient’s respiratory signal was acquired. Two sets of images were reconstructed: 4DCT images derived from the 10 phase images and produced by the proprietary 4D-CT
software, and processed images from cine CT. 4D-CT images included 10 phase images,
MIP4D-CT, and RACT4D-CT. Cine CT images included MIPcine and RACTcine and were produced
directly from the cine CT images using in-house software (Pan et al., 2007). All cine scans
were performed at 120 kV and 100 mA, with the exception of two patients, whose scans
were performed at 150 mA and 80 mA. Gantry rotation period for all patients was 0.5 s.
First, IGTV was auto-segmented on MIPcine and MIP4D-CT for 11 high-contrast lesions
that were not adjacent to dense structures. A seed-based region-growing algorithm in the
treatment planning software was used for contouring. It should be noted, however, that,
although the treatment planning software documentation defines the algorithm as “region
growing,” the technique differs from conventionally-defined region growing. Typically,
region growing occurs on a pixel-by-pixel basis radiating outwards from the seed point until
a threshold is reached (Beutel, 2000). Region growing in the treatment planning system
occurs by searching pixels to the right of the seed point until a threshold is reached, and the
closed boundary around the structure is contoured. The resulting contours were compared
with a paired t-test to investigate patient contouring while minimizing the influence of a
human observer.
One radiation oncologist who specialized in thoracic SBRT delineated the tumors for
all patients using the commercial radiation treatment planning system. The radiation
oncologist first contoured IGTVcine in all patients from high- and low-contrast tumor groups
using MIPcine and RACTcine concurrently. Then, the radiation oncologist contoured IGTV4D-CT
according to the current M. D. Anderson clinical protocol: MIP4D-CT was used to outline an
IGTV and this volume was then edited based on the 4D-CT phase images. All contours were
drawn using the “lung” window/level.
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2.3.3 Analysis
For the phantom study, mean volume magnitudes were compared with a paired ttest to assess observer-independent differences in contouring on cine and 4D-CT image sets
(α = 0.05).
For the patient study, auto-segmented IGTVs were compared with a paired t-test (α
= 0.05). Physician-drawn IGTV4D-CT and IGTVcine volume magnitudes were compared
statistically by taking the ratio of the volume magnitudes and constructing 95% confidence
intervals around the mean ratio and comparing these confidence intervals to the
intraobserver variation. Three lesions in the high contrast group and 3 lesions in the low
contrast group were re-contoured on 4D-CT phase imaging by the radiation oncologist at
least 2 months after initial contouring. Resulting IGTVs were compared with initial 4D-CT
results and the average percent differences represented the intraobserver variation for
each group. Difference in centroid location between IGTV4D-CT and IGTVcine was compared
statistically using a log-normal distribution. 95% confidence intervals were constructed
around the mean centroid shift (geometric mean was used with the logarithmic
transformation) to assess the variability of centroid shift.
Volume overlap was assessed with the Dice Similarity Coefficient index (DSC), which
is a measure of the degree of overlap between two areas or volumes (Dice, 1945; Zou et al.,
2004). If A is a “reference” volume and B is a “test” volume to be compared to the
reference,

 ,

||
||||

(1)

Though the DSC is similar to the concordance index in that small changes in volume yield
large changes in DSC when the volumes analyzed are small, the DSC is normalized to the
sum of the two volumes rather than the union (Giraud et al., 2002). As with any manual
segmentation, some uncertainty exists in the tumor delineation. By normalizing the DSC,
we take both volume size and segmentation uncertainty into account by dividing the DSC in
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equation ( 1 ) by an “uncertainty index” (UI). UI is defined as the DSC of the reference
volume with the reference volume contracted by 1 mm (A-1). This value was chosen
because it reflects the width of one CT pixel in the transverse plane using a 50 cm FOV and
512 by 512 image matrix (which is the typical protocol for CT simulation at M. D. Anderson).
The normalized DSC (NDSC), therefore, was given by

 ,

||
||||
| |
||| |

,


(2)

It is helpful to consider the limiting cases when interpreting this index. Higher DSCs
mean greater agreement between the experimental and reference volumes. If the NDSC is
greater than 1, the DSC of the experimental-to-reference volumes is greater than the
uncertainty index, implying that the volumes agreed to less than 1 mm uncertainty. In the
current study, the reference volume was IGTV4D-CT and the comparison volume was IGTVcine.

2.4

Results

2.4.1 Phantom Study
Ten sets of IGTVcine and IGTV4D-CT auto-segmented at a -700 HU threshold on MIPcine
and MIP4D-CT image sets respectively were compared with a paired t-test. For all 6 spheres
in the phantom, the IGTVcine was significantly larger than IGTV4D-CT (Table 2.1). Most
differences between IGTVcine and IGTV4D-CT occurred in the most superior and inferior slices
of the motion envelope and, by visual inspection, were not caused by in-slice motion
artifact (the spiral patterns often seen when the sphere is present in some projections but
not others were not present). This suggests that the larger IGTVcine better captured the full
extent of motion because MIPcine included images in the maximum intensity processing
which were not present in the 4D-CT. Processing from cine CT, therefore, more accurately
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captures the extremes of a naturally varying waveform because more samples of the
waveform are included.

Table 2.1: Significance values for phantom study
MIP4D-CT (cm3)
Sphere
Mean
Standard
Diameter (cm)
Volume Deviation
3.7
49.8
0.8
2.8
24.9
0.5
2.2
13.7
0.3
1.7
7.9
0.2
1.3
4.4
0.2
1.0
2.5
0.1
MIP = maximum intensity projection

MIPcine (cm3)
Mean
Standard
Volume
Deviation
51.0
1.1
25.7
0.8
14.1
0.4
8.2
0.3
4.6
0.2
2.7
0.1

p
<0.01
<0.01
0.02
<0.01
0.04
0.01

2.4.2 Patient Study
For the auto-segmented volumes of 11 high-contrast lesions, the IGTVcine was
significantly larger than IGTV4D-CT (p=0.02). These results are consistent with the phantom
results of section 2.4.1.
Table 2.2 and Table 2.3 list IGTVcine and IGTV4D-CT measurements and
IGTVcine/IGTV4D-CT ratios of manually segmented volumes for the high- and low-contrast
patient groups respectively. IGTVcine and IGTV4D-CT volumes were not significantly different
(as found by a paired t-test) in patients with high-contrast tumors (p=0.32) or patients with
low-contrast tumors (p=0.29). Comparisons of mean IGTV ratios with intraobserver
variation for high-contrast and low-contrast patient groups are shown in Figure 2.3. The
95% confidence intervals of the low-contrast group indicate the variation between
contouring on cine CT and 4D-CT was within measured intraobserver variation (p<0.05)
(Feng et al., 2006). Interestingly, for the high-contrast group, the distribution was shifted
slightly higher, implying IGTVcine was slightly larger than IGTV4D-CT . This is, however,
consistent with our phantom and patient auto-segmentation results shown above. Mean
centroid shift was 0.9 mm for the high-contrast group and 1.4 mm for the low-contrast
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group. The upper 95% confidence interval was 1.5 mm and 2.0 mm for high- and lowcontrast lesions respectively, indicating that cine CT produces volumes positioned similarly
to those drawn on 4D-CT in high- and low-contrast scenarios.

Table 2.2: Internal gross tumor volume (IGTV) measurements for high-contrast patients.
Patient # IGTVcine IGTV4D-CT Ratio DSC NDSC
(cm3)
(cm3)
1
12.6
9.8
1.28 0.83 0.95
2
11.0
12.6
0.87 0.84 0.98
3
4.8
3.9
1.26 0.78 0.96
4
6.6
6.7
1.00 0.90 1.07
5
15.2
13.8
1.10 0.90 1.01
6
4.3
3.6
1.20 0.81 1.05
7
2.9
2.8
1.04 0.78 0.98
8
11.5
11.2
1.02 0.88 1.02
9*
2.0
2.1
0.94 0.75 0.97
10*
15.1
13.8
1.09 0.86 0.99
11
2.9
2.9
0.99 0.81 0.99
12
6.1
7.3
0.83 0.84 0.97
13
18.6
18.8
0.99 0.87 0.96
Average
8.7
8.4
1.05 0.84 0.99
SD
5.5
5.4
0.14 0.05 0.04
CI95
±0.08
CI90
±0.07
Asterisks (*) indicate bisynchronous lesions.
SD = standard deviation
CI95 = 95% confidence interval
CI90 = 90% confidence interval
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Table 2.3: Internal gross tumor volume (IGTV) measurements for low-contrast patients.
Patient # IGTVcine IGTV4D-CT Ratio DSC NDSC
(cm3)
(cm3)
14
5.0
5.8
0.86 0.84 0.99
15
12.1
11.7
1.04 0.85 0.99
16
21.6
20.2
1.07 0.85 0.95
17
4.1
4.1
0.99 0.82 0.97
18
5.8
6.8
0.84 0.79 0.93
19
8.1
7.9
1.03 0.86 0.98
20
3.0
3.3
0.90 0.74 0.96
21
2.4
2.5
0.97 0.86 1.08
22
22.4
27.1
0.83 0.83 0.92
23
14.0
15.4
0.91 0.88 1.01
24
14.8
15.8
0.93 0.84 0.95
25
38.1
37.5
1.02 0.88 0.97
26
22.1
24.2
0.91 0.82 0.91
27
8.5
6.4
1.33 0.84 0.97
Average
13.1
13.5
0.97 0.84 0.97
SD
10.1
10.5
0.13 0.04 0.04
CI95
±0.07
CI90
±0.06
SD = standard deviation
CI95 = 95% confidence interval
CI90 = 90% confidence interval
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Figure 2.3:: Mean volume magnitudes for high and low contrast tumors. Red error bars
are the 95% confidence interval around the mean. Black error bars represent mean
intraobserver variation for 3 re
re-contoured patients. Reproduced with permission from
Riegel et al. (Riegel et al., 2009)
Table 2.2 and Table 22.3 list results of the DSC analyses for high- and low-contrast
low
groups respectively.. DSCs were well over 0.7, which is considered good overlap (Bartko,
1991; Zou et al., 2004). The mean NDSC for high
high-contrast
contrast tumors was 0.99. The mean
NDSC for low-contrast
contrast tumors was 0.97. Because both values are slightl
slightlyy less than 1, this
implies that the volumes were slightly below the threshold for agreement within 1 mm
uncertainty.
Examples of low-contrast
contrast tumors are shown in Figure 1.5 and Figure 2.4. In Figure
1.5, as previously described in section 1.2, the lung tumor is positioned adjacent to the
chest wall and the anterior, superior, and inferior edges of the tumor that border the lung
are clearly defined on the MIPcine. The posterior edge, however, is adjacent to the higherdensity chest wall and the border is difficult to discern. By using the RACTcine to provide
additional information,, however, the edges become much more apparent; the degraded
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density of the RACTcine provides contrast to define the posterior border. In Figure 2.4, the
liver obscures the lesion on the transverse MIPcine, but the RACTcine reveals the
th transverse
extent of the tumor.

Figure 2.4:: Transverse CT image of tumor adjacent to the liver. (left) Maximum intensity
projection. (right) Respiratory
Respiratory-averaged CT. Reproduced with permission from Riegel et
al. (Riegel et al., 2009)

2.5

Discussion
Our results indicate that SBRT targets drawn with cine CT images sets are similar to

or slightly larger than those drawn by full 10
10-phase 4D-CT image sets.
Bradley et al. found that contours based on MIP4D-CT were significantly larger than
those based on helical CT and RACT4D-CT and concluded that volumes drawn on MIP4D-CT
would presumably be less prone to geometric miss due to the fact they were larger and
more inclusive (Bradley et al., 2006)
2006). A recent dynamic MRI study by Cai et al.,
al. however,
demonstrated that MIP4D-CT underestimated the true extent of tumor motion for lesions
moving irregularly (Cai et al., 2007)
2007). Furthermore, the underestimation was proportional to
the variability of the respiratory pattern. The authors identified limited temporal resolution
and “incomplete sampling strategy” as causes fo
for the underestimation. A second study
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CT to scan a phantom under irregular motion (similar to the current study) found
using 4D-CT
results consistent with our findings (Park et al., 2009). In the current study, we have shown
that segmenting on MIPcine produces larger IGTVs in phantoms and patients.
patients Following the
findings of Bradley and Cai, p
processing
rocessing the MIP from cine CT improves the limited sampling
of the MIP4D-CT image set because it includes the complete set of cine images at each couch
position, not just a 10-phase
phase subset.

Figure 2.5:: Observed motion extent in 4D
4D-CT
CT (top) versus observed motion extent in
MIPcine. Note that in 4D-CT,
CT, images that reflected the full motion extent were not
included in the phase imaging. In MIPcine, however, all images are included and maximum
motion extent is imaged. Reproduced with permission from Riegel et al. (Riegel
(Ri
et al.,
2009)
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When more than one breathing cycle of a naturally varying respiratory waveform is
imaged in 4D-CT acquisition, it is possible that the end inspiration (0%) and end expiration
(50%) phases will not include the images that represent the largest motion extent of a
tumor. Including more samples in the MIP process will increase the chances that the
largest motion extent is imaged. This most likely explains the results of the phantom and
patient auto-segmentation studies (where IGTVcine was significantly larger than IGTV4D-CT)
and this effect is demonstrated diagrammatically in Figure 2.5. As we previously found that
90% of patients have average breathing cycle periods of less than 6 s (Pan et al., 2006), we
recommended that cine durations of 6 s be chosen for cine CT acquisition (Chi et al., 2007).
One can increase the cine duration beyond one average breathing cycle, however, to
provide better sampling of the varying respiratory waveform and produce a more
encompassing MIPcine image set.
One limitation of our method is that processing directly from cine CT will include
rare respiratory irregularities such as coughing in the image sets. This is undesirable
because such discontinuities represent relatively infrequent events that should not be
included in treatment planning. Isolating these effects by manually removing cine CT
images affected by such an event is possible (Pan et al., 2007).
In the manual segmentation study of patient images, cine-CT-based radiation
treatment planning performed as well as 4D-CT. The results of our study show that
including RACTcine in the delineation process with MIPcine is sufficient in producing IGTVs
similar (within intraobserver variability) to those formed with full 4D-CT for lesions adjacent
to tissue of equal or greater density. Several authors have cautioned against using MIP in
these cases (Muirhead et al., 2008; Rietzel et al., 2005; Rietzel et al., 2008; Underberg et al.,
2005), and one group has recommended that RACT not be used for contouring because the
edges of the tumor are blurred by motion (Bradley et al., 2006). A group from the
Netherlands, however, has advocated using RACT with a colormap to highlight degrees of
motion (Cover et al., 2006). Figure 1.5 and Figure 2.4 demonstrate the benefit of using MIP
and RACT together for moving tumors.
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CT (top row) and cine CT
Figure 2.6:: Maximum intensity projections processed from 4D-CT
(bottom row). Red contours are IGTVcine and green are IGTV4D-CT. Note that cine CT
captures several slices of tumor motion beyond that captured by 4D
4D-CT. Reproduced with
permission from Riegel et al
al. (Riegel et al., 2009)
Itt is interesting that IGTV4D-CT and IGTVcine were not equivalent in the high-contrast
high
group of tumors, where the lesions were not adjacent to dense structures. Mean IGTVcine
was larger, though not significantly, than IGTV4D-CT. This result can most likely be attributed
to two factors: First, the average volume of high
high-contrast
contrast tumors was approximately twotwo
thirds the average volume of low
low-contrast
contrast tumors, so an identical volume difference
between IGTVcine and IGTV4D--CT in both groups would be a larger percentage difference in
the first group than in the second, which would affect the volume ratio. Second, as
described in the discussion above, MIPcine uses the entire set of cine CT images for
processing (between 20-30
30 images pe
perr slice location), which is a larger sample than MIP4D-CT
processing (10 images per slice location). The larger IGTVcine in the manually-contoured
manually
high-contrast tumors is consistent with the results of the patient and phantom autoauto
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segmentation studies. Figure 2.6 illustrates this effect for patient 1, whose IGTVcine/IGTV4DCT

volume ratio was the second largest of all 27 patients. MIP4D-CT and MIPcine images are

shown that highlight the region of increased density at the inferior region of the tumor in
the MIPcine, which is not present in the MIP4D-CT.
Though cine- and 4D-CT-defined tumor contours for treatment planning showed
good agreement over the entire sample, individual cases still demonstrated the pitfalls of
using MIP for contouring. Three patients with the lowest NDSC values (patients 18, 22, 26)
all had lesions near the diaphragm where it was difficult to determine inferior extent
because of overlap with the liver, even when contouring with RACT image data. These
patients could potentially benefit from target definition with PET. In section 5.4.1, patient
26 is revisited using MIPcine and PET together for contouring.
Cine acquisition mode is not unique to General Electric CT scanners and other
groups have explored cine CT with scanners of different manufacture (Low et al., 2003;
McClelland et al., 2006), but cine acquisition on other CT scanners is more complicated and
less efficient than the GE implementation. Other manufacturers use a series of axial
acquisitions at the same couch position rather than continuously acquiring data and
reconstructing an image series retrospectively. Furthermore, the ability to scan a large area
seems to be limited by protocol setup. For 4D-CT, Philips and Siemens both use a low-pitch
helical acquisition mode which requires a respiratory trace to reconstruct images (Keall et
al., 2004; Pan, 2005). In theory, low-pitch helical data could be subjected to “cine type”
processing discussed in this chapter, but data that are not included in 4D-CT reconstruction
cannot be accessed easily after reconstruction is completed due to the prospective nature
of the scan. In the future, it may be possible to implement a similar reconstruction process
to low-pitch helical data, but no such method has yet been developed.
Curiously, the GE 4D-CT sorting software enables the user to create MIP and RACT
directly from cine CT instead of the 10 phases, but a respiratory trace is still required to
initialize the program even though it is not used for the desired operation. Our software
operates on a simple personal computer and bypasses the need for a respiratory trace.
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2.6

Conclusions
As described in section 1.2, 4D-CT is complex and costly for many cancer centers.

The motion information it provides, however, is extremely important in accurately targeting
lung cancer and reducing treatment margins, thereby sparing additional normal tissue. This
chapter has presented a cost-effective alternative to 4D-CT for treatment planning that
does not require additional hardware or commercial software beyond that already available
on scanners already in use. Creating MIP and RACT directly from the cine CT images and
using these images sets together to define targets for SBRT produces volumes that are
similar to those drawn by full 10-phase 4D-CT.
The results of this chapter pertain mainly to small, mobile lesions. We anticipated
that, for larger tumors and later-stage lung cancer (such as stage III, for which IMRT in
conjunction with chemotherapy is a curative treatment modality for inoperable disease
(Furuse et al., 1999; Govindan, 2003)), the use of cine CT in treatment planning will be
limited because of more complicated involvement with surrounding tissue (Muirhead et al.,
2008). In chapters 4 and 5, attempts to incorporate positron emission tomography (PET)
into the cine CT treatment planning process are described. PET/CT may provide additional
contrast for target definition in cases with complicated tumor involvement with
surrounding tissue. Several studies have analyzed the impact of including PET data in GTV
delineation for NSCLC and have yielded noteworthy results, mostly due to the inclusion of
lymph nodes and exclusion of atelectasis (Bradley et al., 2004; Nestle et al., 1999; van
Baardwijk et al., 2006). Those studies suggest that metabolic information from PET helps
physicians discriminate between normal and malignant tissue that is indistinguishable on CT
alone, which can sometimes occur when using MIP.
Another subject not covered in this chapter yet still an important aspect of
treatment planning is dose calculation. This topic is covered in chapter 3.
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Chapter 3 DOSE CALCULATION WITH CINE RESPIRATORY-AVERAGED CT

3.1

Introduction
In the previous chapter, the important aspect of tumor delineation on MIPcine and

RACTcine was discussed. In this chapter, dose calculation with RACTcine is explored. After the
tumor is delineated, the appropriate margins are added, and beam arrangements have
been planned, the resulting dose distribution is calculated. Convolution-superposition, a
typical calculation algorithm, operates by integrating the product of the primary photon
fluence from each beam, a convolution kernel or “dose spread array” that can be obtained
by measurement or Monte Carlo simulation, and the mass attenuation coefficient provided
by the CT image set (Khan, 2003). Note that linear attenuation coefficients obtained at
diagnostic energies must be scaled for use in the therapeutic (megavoltage) range.
Typically, dose is calculated on a free-breathing helical CT data set. However, artifacts
during image acquisition due to respiratory motion are well-known (Chen et al., 2004;
Gagne et al., 2004).
Dose calculation based on 4D-CT data sets has been explored (Flampouri et al.,
2006; Guckenberger et al., 2007; Keall et al., 2004; Rietzel et al., 2005). These calculation
methods generally apply a 3-D treatment plan to each phase of the 4D-CT data set, equally
divide the number of monitor units among each of the phases, and register the resulting
dose distributions to a reference phase using rigid or deformable registration. Though not
truly 4-D treatment planning, this calculation methodology should provide a more accurate
estimate of how dose is distributed over a respiratory cycle than calculation on a single,
presumably stationary image set. Currently, however, this methodology is not commonly
used clinically.
Guckenberger et al. compared dose calculation on 3-D and 4-D image sets by
recalculating dose on different phases of the 4D-CT and comparing these distributions to 4D dose calculation described above. This study demonstrated minimal dosimetric
differences for GTV and ITV in the two methods (Guckenberger et al., 2007), suggesting that
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full 4-D dose calculation using all phases of imaging may not be necessary to estimate dose
to a moving target. Producing 3-D image sets that reflect respiratory motion, however, still
requires 4D-CT; end-inspiration and end-expiration scans are generally not reliable (Pan et
al., 2005). Admiraal et al. demonstrated that dose calculation on RACT4D-CT, the pixel-bypixel average of the 10 phases of 4D-CT, produces similar results to the dose calculation
methodology described above (Admiraal et al., 2008). The use of RACT4D-CT for dose
calculation has been adopted at M. D. Anderson because RACT4D-CT represents moving
structures more accurately than free-breathing helical CT or end-inspiration/expiration
imaging over a fraction of radiation.
As the last chapter explored the use of MIPcine and RACTcine for target delineation, a
logical question is whether or not RACTcine could replace RACT4D-CT for dose calculation.
RACTcine, however, averages all the images at each couch position, which can over- or
under-emphasize different parts of the respiratory cycle in the CT number averaging
process (Chi et al., 2007). This can be demonstrated with a simple example. From calculus,
the mean of any function is:
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If we consider the respiratory trace as a simple sine function, the mean of the sine function
is:
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Figure 3.1 illustrates the sine function and the mean of the sine function. When x =

2πk (where k are integers), cos!

!
1 and """"""

0. This is comparable to RACT4D-CT: Ten

image sets are chosen to represent equally-spaced phases of one respiratory cycle, like 1
! reaches a maximum at x ≈ 3π or 1.5
period of a sine wave (k = 1). When x ≥ 2π, """"""
breathing cycles. RACTcine, therefore, will be most different from RACT4D-CT when
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approximately 1.5 breathingg cycles are captured in 1 cine duration (CD). RACTcine will be
“weighted” towards one-half
half of the respiratory pattern more than the other,
other which may
have a significant impact on dose calculation (Chu et al., 2000; Geise et al., 1977).
1977) Another
feature of Figure 3.1 is the presence of an “envelope”
velope” function (1/x) which causes the
overall function to decrease with increasing x.. Consequently, increasing the number of
images acquired at each couch position (e.g. increasing the CD)) should make RACTcine more
similar to RACT4D-CT.

Figure 3.1:: sin(x) and the average of sin(x). Reproduced with permission from Riegel et
al. (Riegel et al., 2008)

3.2

Purpose
The purpose of this chapter was to evaluate the difference in dose calculation on

RACT4D-CT and RACTcine. We hypothesized that differences between the dose distributions
would be negligible and that differences would decrease as CD increases (because more
imaging samples of the respiratory cycle are included in the averaging process).
Successfully demonstrating
ating that RACTcine can replace RACT4D-CT for dose calculation could
provide an image set which emulates 44-D dose calculation to treatment centers without
40

access to 4D-CT. This, in conjunction with the results of Chapter 2 , lends further support to
our over-arching hypothesis that image sets processed from cine CT can replace 4D-CT
image sets for treatment planning purposes with negligible differences.

3.3

Methods

3.3.1 Patient Study
Twenty-three lung cancer patients who received 4D-CT simulation as part of their
radiation therapy were retrospectively included in the “primary” patient group. These
patients had an average of at least 2 breathing cycles per CD. The respiratory patterns were
classified as “regular” or “irregular” by calculating the coefficient of variation (COV) of the
respiratory period over the duration of the scan. The COV was defined as the standard
deviation over the mean expressed as a percentage. COVs <10% were considered regular
and those >10% were considered irregular. We anticipated the over/under-emphasis
phenomenon will affect patients with regular breathing cycles more because the same
fraction of the breathing cycle will be averaged for every couch position, though the phase
will be different (Figure 3.2). Table 3.1 summarizes the patient respiratory characteristics.
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yellow
Figure 3.2:: Overemphasis of sections of the respiratory pattern. The yellow-shaded
region represents one period of the respiratory cycle and the orange
orange-shaded
shaded region is the
part of the breathing cycle averaged twice in RACTcine, thereby “weighting” the image
towards
ds the repeated phase of the breathing cycle. Reproduced with permission from
Riegel et al.
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Table 3.1: Primary group patient characteristics.
Tx
Patient #
Location Avg. T (s) CD/Avg. T COV (%)
1
Lung
2.2
2.0
4.3
IMRT
2
Lung
2.7
2.2
4.4
IMRT
3
Lung
2.3
2.2
4.8
IMRT
4
Liver
2.5
2.2
6.4
3DCRT
5
Esophageal
1.8
2.5
6.7
IMRT
6
Lung
2.1
2.4
6.8
IMRT
7
Lung
2.7
2.2
7.8
SBRT
8
Lung
1.9
2.1
7.9
SBRT
9
Lung
1.6
2.5
8.0
IMRT
10
Lung
2.1
2.1
8.9
SBRT
11
Liver
3.0
2.3
9.7
IMRT
12
Lung
2.6
2.2
11.2
IMRT
13
Lung
2.3
2.2
12.9
SBRT
14
Lung
2.2
2.3
13.0
IMRT
15
Lung
3.5
2.1
16.1
IMRT
16
Lung
3.2
2.2
18.9
3DCRT
17
Lung
2.7
2.2
20.5
IMRT
18
Esophageal
1.9
2.3
20.5
IMRT
19
Lung
3.1
2.3
22.6
IMRT
2.6
2.3
26.2
3DCRT
20
Esophageal
21
Lung
2.2
2.3
34.0
IMRT
22
Lung
2.3
2.3
37.0
IMRT
23
Lung
2.6
2.5
37.2
IMRT
Average
2.4
2.3
0.5
0.1
Standard Dev.
Avg. T = average breathing cycle
CD = cine duration
COV = coefficient of variation
Tx = treatment technique
IMRT = intensity modulated radiation therapy
SBRT = stereotactic body radiation therapy
3DCRT = 3-D conformal radiation therapy.
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All 4D-CT simulations were performed on an 8-slice General Electric Discovery ST
PET/CT scanner (GEMS, Waukesha, WI) in cine mode with 2.5 mm slice thickness, 50 cm
field-of-view, and 512 by 512 image matrix producing a pixel size of 0.97 × 0.97 × 2.5 mm3.
RACTcine was processed from the same cine CT from which the simulation 4D-CT was
formed, thereby eliminating the need to expose the patient to further irradiation. A
different number of images were included in each RACTcine to simulate fractions of the
breathing cycle being captured at each couch position (1 breathing cycle, 1.5 breathing
cycles, and 2 breathing cycles). These image sets are designated RACTcine1, RACTcine1.5, and
RACTcine2 in this chapter.
The clinical treatment plan was copied to each RACTcine image set and dose was
recalculated using CCC on a 4 mm isotropic grid with Pinnacle3 version 7.6. Sagittal,
coronal, and transverse dose planes through the isocenter were interpolated to 1 mm pixels
and exported for RACT4D-CT, RACTcine1, RACTcine1.5, and RACTcine2 treatment plans.
Because the clinical protocol for 4D-CT is to set the CD to 1 breathing cycle plus 1
gantry rotation (Pan et al., 2004), the number of patients in the study is small.
Furthermore, the average breathing period of these patients was relatively short. We
therefore performed a follow-up study with a larger number of patients and longer
breathing periods more typical of clinical exams. Fifty (50) lung cancer patients whose
clinical dose calculation was performed on RACT4D-CT were included for comparison. This
group was designated the “follow-up” patient group. Table 3.2 summarizes patient
characteristics for the follow-up patient group. Of these 50 patients, 25 received SBRT and
25 received IMRT. As before, RACTcine was reconstructed using the same cine CT data as the
4D-CT simulation. Averaging, however, was only performed with the maximum number of
images at each couch position (as would be performed clinically in our cine CT-based
planning paradigm). As before, the clinical plan was copied to the RACTcine image set, dose
was recalculated, and dose distributions on RACT4D-CT and RACTcine were compared.
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Table 3.2: Follow-up group patient characteristics.
IMRT
SBRT
Patient # Avg. T (s) CD/Avg. T
Patient # Avg. T (s) CD/Avg. T
1
7.0
1.3
26
3.4
1.6
2
6.2
1.2
27
4.6
1.7
3
6.2
1.1
28
3.1
1.6
29
4.9
1.3
4
6.2
1.2
5
6.2
1.2
30
5.2
1.2
6
6.2
1.2
31
----32
4.2
1.4
7
6.1
1.2
8
5.8
1.3
33
5.6
1.3
34
5.7
1.6
9
5.5
1.3
10
5.3
1.3
35
4.5
1.6
11
5.2
1.1
36
2.6
1.9
37
6.0
1.6
12
5.2
1.3
13
5.1
1.4
38
4.6
1.9
14
5.1
1.5
39
7.9
1.5
40
7.6
1.2
15
5.0
1.4
16
4.8
1.3
41
5.9
1.0
17
4.7
1.3
42
5.2
1.3
43
4.9
1.1
18
4.7
1.3
19
4.6
1.3
44
4.8
1.3
20
4.5
1.1
45
4.7
1.2
46
4.7
1.3
21
4.4
1.4
22
4.4
1.6
47
4.7
1.7
23
4.4
1.4
48
4.6
1.4
49
4.4
1.3
24
4.4
1.4
25
4.3
1.4
50
4.1
1.4
Average
4.9
1.4
Average
5.3
1.3
SD
0.8
0.1
SD
1.2
0.2
Respiratory trace could not be retrieved for patient 31.
For abbreviations, see Table 3.1.
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3.3.2 Analysis
RACTcine plans were compared to the RACT4D-CT plan using the gamma (γ) index
(Depuydt et al., 2002; Low et al., 1998; Low et al., 2003) inside the planning target volume
(PTV). The γ index is defined in equations ( 5 ) and ( 6 ). The variables re and rr represent
points on the evaluated and reference distributions respectively, where d and D are the
distance-to-agreement and dose difference pass/fail criteria selected by the user.
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Pass/fail criteria for the γ index are typically 5%/3 mm or 3%/3 mm in clinical
situations such as IMRT quality assurance (Depuydt et al., 2002; Low et al., 1998; Low et al.,
2003). In these cases, dose distributions are calculated in a phantom and are compared to
film measurements. Since we compared two calculated distributions, the pass/fail criteria
were tightened to 2%/1mm to reflect a lower percent dose difference limit of dose
calculation accuracy (Papanikolaou et al., 2004) and the spatial resolution of the CT scanner
in the transverse plane with a 512 × 512 image matrix and 50 cm FOV.
DOSELAB software, a publicly-available dose-comparison software package, was used
to calculate γ indices in each of the 3 orthogonal planes (Childress et al., 2003; Childress et
al., 2005). Dose planes contained the full extent of the dose grid. The intersection of the
clinical PTV and the orthogonal dose planes were the areas of interest (Figure 3.3).
Maximum and mean γ indices and percentages of points passing the γ criteria were
measured for these areas. The PTV was formed clinically according to the procedure
described in a recent publication from authors at M. D. Anderson (Ezhil et al., 2009). First,
the IGTV was formed by contouring the “motion envelope” on MIP4D-CT and confirming
extent on the 4D-CT phase images. The IGTV was expanded to the internal clinical target
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volume (ICTV) using an 8 mm isotropic expansion. The ICTV was expanded to the PTV with
a 5 mm or 3 mm expansion depending on the type and frequency of image guidance
gui
utilized
in treatment. For PTVs with multiple regions, a weighted average of the γ index in each
region was calculated.

Figure 3.3:: Intersection of planning target volume (PTV) and orthogonal dose planes.
Reproduced with permission from Riegel et al. (Riegel et al., 2008)
For the primary group of patients, γ indices for RACTcine1 vs. RACT4D-CT
CT, RACTcine1.5 vs.
RACT4D-CT, and RACTcine2 vs. RACT4D-CT were calculated and compared using a one-way
one
analysis of variance (ANOVA)
VA) for correlated samples with a post
post-ANOVA
ANOVA Tukey HSD test to
detect any statistically significant differences between the dose calculations on image sets
s
of increasing CD (Lowry, 2008
2008). We anticipated that maximum and mean γ indices would
decrease with increasing CD.. For the follow
follow-up
up group of patients, γ indices were calculated
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for the RACTcine vs. RACT4D-CT comparison. Note that statistical analysis was not performed
because only one comparison was performed for the follow-up group.

3.4

Results

3.4.1 Primary Patient Group
For the RACTcine1 vs. RACT4D-CT and RACTcine1.5 vs. RACT4D-CT comparisons, 22 of 23
patients demonstrated 100% of points within the PTV on coronal, sagittal, and transverse
planes passing our 2%/1mm γ criteria. The lone patient who demonstrated any failing
points had 1.4% and 0.3% of points fail on coronal and sagittal planes respectively for the
RACTcine1 vs. RACT4D-CT comparison. Though already extremely low, the failures decreased to
0.6% and 0% on coronal and sagittal planes respectively in the RACTcine1.5 vs. RACT4D-CT
comparison, then disappeared completely in the RACTcine2 comparison. All patients
demonstrated 100% passing points within the PTV for all geometrical orientations in the
RACTcine2 vs. RACT4D-CT comparison.
Maximum and mean γ indices for the RACTcine1, RACTcine1.5, and RACTcine2
comparisons within the PTV for regular respiratory patterns are shown in Figure 3.4 and
results for irregular respiratory patterns are shown in Figure 3.5. Maximum and mean
values are very low, well under 1, which demonstrates that dose calculation on RACTcine is
very similar to dose calculation on RACT4D-CT, regardless of how many breathing cycles are
used for averaging. The data shows, however, that increasing the CD does, in general,
decrease the γ index to even lower levels. The maximum and mean γ indices from the
RACTcine2 vs. RACT4D-CT comparison are significantly lower than the RACTcine1 vs. RACT4D-CT and
RACTcine1.5 vs. RACT4D-CT indices for several comparisons (coronal and transverse plane) with
irregular respiration (arrows in Figure 3.5). The RACTcine1.5 vs. RACT4D-CT γ indices were not
significantly higher for regular respiration, contrary to what we had anticipated.
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Figure 3.4:: (A) Maximum and (B) mean gamma (γ) indices for patients with regular
respiratory patterns. Error bars are standard error (N=11). Reproduced with permission
from Riegel et al. (Riegel et al., 2008)

49

Figure 3.5:: (A) Maximum and (B) mean gamma (γ) indices for patients with irregular
respiratory patterns. Error bars are standard error (N=12). Green arrows are significant
differences as determined by ANOVA/Tukey HSD tests. Reproduced with permission
perm
from
Riegel et al. (Riegel et al., 2008)
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3.4.2 Follow-up Patient Group
Gamma criteria were met for 100% of points within the PTV for 49 of 50 patients.
Patient 22 had 1% of points within the PTV fail the 2%/1mm criteria on the coronal γ
distribution.
Figure 3.6 shows the maximum and mean γ indices within the PTV for the 3
orthogonal dose planes. All are well below 1, again supporting that calculation on RACTcine
is very similar to calculation on RACT4D-CT. Figure 3.7 compares maximum and mean γ
indices within the PTV for SBRT and IMRT treatment techniques. The maximum γ index is
higher in IMRT treatment techniques, but the mean γ index is higher in SBRT treatment
techniques. This discrepancy is most likely caused by the small PTVs utilized in SBRT: Dose
was calculated using a 4 mm isotropic grid interpolated to 1 mm on each dose plane for γ
analysis. A 4 × 4 × 4 mm3 cube occupies a larger percentage of the total volume for a small
volume than a large volume, thereby weighting the mean towards the higher γ value.
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Figure 3.6:: (A) Maximum and (B) mean gamma indices inside the PTV for the follow-up
follow
patient group. Error bars are standard error. Reproduced with permission from Riegel et
al. (Riegel et al., 2008)
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Figure 3.7:: (A) Maximum and (B) mean gamma indices inside the PTV for the follow-up
follow
patient group, separated by treatment technique. IMRT = intensity modulated radiation
therapy. SBRT = stereotactic body radiation therapy. Reproduced with permission from
Riegel et al. (Riegel et al., 2008)
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3.5

Discussion
Several authors have explored 4-D dose calculation (Flampouri et al., 2006;

Guckenberger et al., 2007; Keall et al., 2004; Rietzel et al., 2005), but the technique is not
commonly used clinically due to the need for 4D-CT (which, as described above, is not
readily available for many institutions) and increased calculation time. At M. D. Anderson,
dose calculation with RACT4D-CT is currently utilized for treatment planning of thoracic
lesions. Admiraal et al. have shown that this technique can produce similar results to 4-D
dose calculation (Admiraal et al., 2008). We developed a technique to create RACT image
sets directly from the cine CT images which does not require a respiratory trace or sorting
into phase or amplitude bins. RACTcine, however, is not identical to RACT4D-CT: Including all
the cine CT images in RACT processing may cause CT number differences from the RACT4DCT.

An early paper by Geise et al. cites that a 4-10% change in electron density may produce

a 2% error in dose (Geise et al., 1977). In the case of regions highly affected by motion,
especially irregular motion, CT number fluctuation may exceed this limit.
The current chapter has shown that calculating dose on RACTcine image sets is
negligibly different than calculating dose on RACT4D-CT. Discrepancies can be decreased
further by including more than one period of a respiratory pattern in each CD of cine CT
(Figure 3.4 and Figure 3.5). Patient 22 in the primary group was the only patient to
demonstrate any points failing the 2%/1mm γ criteria in the RACTcine1 and RACTcine1.5
comparisons, but these failing points disappeared as the CD increased to 2 breathing cycles.
Our findings suggest that RACTcine could replace RACT4D-CT for the purposes of dose
calculation with negligible differences in resulting dose distributions.
As briefly described in section 3.3.1, the first set of patients suffers from several
problems: First, the sample size is small because the typical criteria for CD selection is 1
average breathing cycle plus 1 gantry rotation (Pan et al., 2004), therefore making patients
with 2 breathing cycles per CD rare. Second, as a consequence of the first point, some
patients with esophageal or liver malignancies were added to the core of lung cancer
patients to increase sample size. Third, patients with multiple respiratory cycles per CD are
often breathing rapidly and the average respiratory periods of these scans are typically
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smaller than those of the general population receiving 4D-CT. The average breathing period
of patients used in the first part of the study was less than 3 s, while most patients have a
breathing period between 4 and 5 s (Pan et al., 2006).
To address these concerns, we included a second “follow-up” set of 50 lung cancer
patients whose respiratory periods were closer to the population average. Multiple
RACTcine image sets, however, could not be reconstructed because less than 2 breathing
cycles were captured at each couch position. The fact that γ analysis of the follow-up
patient group is similar to results of the first supports the conclusion that RACTcine is
sufficiently similar to RACT4D-CT for dose calculation.
Patient 40 demonstrated a substantial change in density distribution from motion
blurring on RACT4D-CT and RACTcine. Patient 40 was also the only patient to show failing
points in the follow-up group of patients. The differing density values caused the observed
disagreement in dose distributions, particularly at the superior and inferior regions of the
tumor, which was located near the diaphragm (Figure 3.8). Regardless, the regions of
disagreement were small and the points failing within the PTV represented only 1% of the
PTV volume. Other patients demonstrated similar differences near high contrast
boundaries, though not beyond our 2%/1mm failure criteria.
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Figure 3.8:: (A) Coronal RACT4D-CT and (B) Coronal γ distribution for patient 40 of the
follow-up
up group. Note that our 2%/1mm γ criteria are violated at the maximum extents
of tumor motion. Reproduced with permission from Riegel et al. (Riegel et al., 2008)
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Even when changes in motion blur occur outside the target volumes themselves,
high-motion
motion areas can still affect dose agreement within the PTV. Moving structures in the
beam path can modulate the depth dose curves, which can cause “shadows” of dose
disagreement behind moving structures. As an example, Figure 3.9 uses the end-inspiration
and end-expiration phases of a 44D-CT to demonstrate this effect with dose calculated for
one oblique beam. Figure 3..10 shows images and γ distributions from patient 20 of the
primary group where this effect can be observed. Because coplanar beams enter the
patient parallel to thee transverse plane, this may explain why “shadowing”
hadowing” effects
transverse slices more than coronal or sagittal slices. This is supported by Figure 3.4 and
Figure 3.5, where the RACTcine1.5 mean γ index is greater, though not significantly, than the
RACTcine1 mean γ index inside the PTV for regular and irregular respiration on transverse
slices only, not coronal
oronal or sagittal.

Figure 3.9:: The "dose shadowing" effect, demonstrated by calculating dose on endend
inspiration and end-expiration
expiration of a 4D
4D-CT
CT and comparing the distributions. The difference
image (A) between the end--inspiration phase CT and end-expiration
expiration phase CT highlight
changes in anatomy due to motion. The gamma (γ) index distribution for a single oblique
beam (B) shows the streaks of dose disagreement behind the moving anatomy.
Reproduced with permission from Riegel et al. (Riegel et al., 2008)
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Figure 3.10:: Shadowing effect seen in patient 20 of the primary group. Pink arrows
highlight areas of moving anatomy on the coronal RACT4D-CT (A) and transverse RACT4D-CT
(B). Stripes of disagreement can be seen medial to the beam entrances behind the
moving anatomy. Reproduced with permission from Riegel et al. (Riegel et al., 2008)
This geometric ambiguity could be remedied by performing a true 33--D γ analysis, not
a 2-D γ analysis of 3 orthogonal plane
planes of dose through the isocenter as executed in this
chapter. At the time this study was performed, no such analytical tool existed at our
institution. Spezi et al. suggested that an approximate 3-D γ analysis could be created
performing 2-D γ analyses on successive dose planes and “stacking” the slices to form a 3-D
γ distribution (Spezi et al., 2006)
2006). Several authors have demonstrated,, however, that
indices in a full 3-D
D γ distribution are less than indices in a “stack” of 22-D
D γ distributions
(Gillis et al., 2005; Spezi et al., 2006; Wendling et al., 2007)
2007). Given the low γ indices
encountered in this chapter,, we do not expect a “stacked” 33-D
D analysis or a true 3-D
3
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analysis (which would produce lower values than a stacked analysis) to yield significant (if
any) failures using our established criteria.
We had originally anticipated that irregular respiratory patterns would be less
affected by the over-emphasis averaging than regular respiratory patterns. As explained
briefly in section 3.3.1, for regular respiratory patterns, the same fraction of the respiratory
cycle is emphasized at each couch position. The over-emphasized phase, however, is
different each time. The results of section 3.4.1 and Figure 3.4 and Figure 3.5 have shown
this to be untrue: Disagreement was approximately twice greater for 1, 1.5, and 2
breathing cycle RACTcine image sets visualizing irregular respiratory motion. This greater
disagreement can most likely be attributed to extreme changes in respiratory amplitude,
which can produce severe artifacts on RACT images (Gould et al., 2008). Recall, however,
that respiratory patterns were classified as “regular” and “irregular” by period not
amplitude. Respiratory frequency and amplitude are often correlated (Davis et al., 1975),
which would explain why artifacts caused by irregular amplitude would show up with
patients separated by irregularity of respiratory period. These artifacts are localized to the
“slabs” of tissue imaged at each couch position defined by the beam width, but may occur
at multiple couch positions if the irregularity persists through the entire scan.
The results of Chapter 2 and Chapter 3 suggest that increasing the CD during cine CT
acquisition will produce better results for both target delineation (to better capture the
extremes of an irregular breathing pattern) and dose calculation. Increasing CD, however,
increases scan time and patient dose. Previous experience with cine CT has shown that
RACTcine and MIPcine can be produced using as little as 40 mA and still maintain acceptable
image quality, which could drastically reduce patient dose from a cine CT scan (Pan et al.,
2007).
While the negligible differences between RACTcine and RACT4D-CT for dose calculation
is encouraging, it is important to note that the similarity of RACTcine to RACT4D-CT for dose
calculation does not necessarily imply similarity of RACTcine to 4-D dose calculation. We did
not explicitly compare RACTcine to 4-D dose calculation. This topic should be investigated.
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Given the low γ indices produced in spite of conservative 2%/1mm γ criteria, however, we
do not expect that additional differences would be significant.

3.6

Conclusions
The previous two chapters focused on applying image sets processed from cine CT to

different, but equally important, parts of the treatment planning process: Target
delineation ( Chapter 2 ) and dose calculation ( Chapter 3 ). For tumors influenced by
respiratory motion, RACT generated from unsorted cine CT images provided a similar
environment for dose calculation as RACT generated from sorted, 10-phase 4D-CT images.
Substituting RACTcine for RACT4D-CT for the purposes of dose calculation can provide centers
without 4D-CT access to an image set that may emulate 4-D dose calculation.
The results of the previous two chapters support the over-arching hypothesis that
image sets processed from cine CT can be used for treatment planning of mobile thoracic
lesions. As described in section 2.6, however, target delineation was only shown for small
lesions. The next chapter explores the incorporation of PET/CT to aid in segmentation of
larger mobile tumors using an automatic segmentation algorithm.
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Chapter 4 SEGMENTATION OF MOVING TARGETS WITH PET/CT: CORRELATION OF
THRESHOLDS WITH LESION SIZE, MOTION EXTENT, AND SOURCE-TO-BACKGROUND
RATIO

4.1

Introduction
The use of fluorodeoxyglucose positron emission tomography (FDG-PET) in the

treatment planning process for lung cancer has become popular in recent years due to
evidence that data from PET imaging can significantly change various aspects of treatment.
Several studies have found that incorporating PET information into CT simulation can
change treatment intent from curative to palliative (Brink et al., 2004; Ciernik et al., 2003;
Dizendorf et al., 2003; Mah et al., 2002), reduce interobserver variation (Ashamalla et al.,
2005; Caldwell et al., 2001; Ciernik et al., 2003; Mah et al., 2002), and alter GTV delineation
where PET effectively discriminates between malignant tissue and atelectasis (Ashamalla et
al., 2005; Erdi et al., 2002; Nestle et al., 1999; van Baardwijk et al., 2006). Recall from
Chapter 2 that we successfully demonstrated target delineation of small, mobile stage I
NSCLC using image sets processed from cine CT, but based on findings by Muirhead et al.
(Muirhead et al., 2008) and common clinical experience at M. D. Anderson, we anticipated
that these image sets alone would be insufficient for treatment planning of larger tumors.
We hypothesized that PET would provide additional information to make target delineation
possible.
Target volume delineation of lung cancer with PET/CT has been extensively reported
in the literature (Biehl et al., 2006; Black et al., 2004; Brambilla et al., 2008; Caldwell et al.,
2003; Davis et al., 2006; Drever et al., 2007; Erdi et al., 1997; Nestle et al., 2005; Okubo et
al., 2008; Park et al., 2008; Paulino et al., 2004), yet little consensus exists on exactly how to
use PET to define a GTV (van Baardwijk et al., 2006). One of the first studies by Erdi et al.
found that 36-44% of maximum activity concentration (ACmax) correlated well with known
sphere volumes in a stationary phantom (Erdi et al., 1997). In a later publication, the group
settled on a single threshold of 42% (Erdi et al., 2002). Paulino et al. suggested an SUV
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threshold of 2.5 g/mL (Paulino et al., 2004), a value that originated from differentiation of
benign versus malignant lesions in PET imaging of NSCLC (Patz et al., 1993).
Subsequent publications questioned the use of a single threshold and proposed
other techniques. As described in section 1.2, several studies show that target size and
source-to-background ratio (SBR) are important parameters (Biehl et al., 2006; Brambilla et
al., 2008; van Baardwijk et al., 2007). Nestle et al., in an attempt to incorporate background
into the contouring scheme, proposed thresholds at 15% of mean activity concentration
plus background activity concentration (Nestle et al., 2005). Black et al., using phantom
scans of different-sized spheres, developed a linear function of mean standardized uptake
value (SUVmean) (Black et al., 2004). Few studies, however, investigated motion as a
parameter for threshold-based automatic segmentation of the PET image. Caldwell et al.
found conventional segmentation techniques produced volumes too small to cover the
motion extent of the tumor on PET imaging. They suggested using a threshold at 15% of
ACmax to include motion (Caldwell et al., 2003). In a subsequent study attempting to define
a motion-inclusive tumor volume, Okubo et al. found that 35% was the optimal threshold
for large stationary or moving spheres. Given the shortcomings of single threshold values
for stationary objects, however, the validity of single-threshold values for segmentation of
motion-inclusive target volumes remains questionable.

4.2

Purpose
The purpose of this chapter was to develop a threshold-based segmentation

technique that accounted for tumor size, motion, and SBR. We therefore modeled activity
concentration threshold dependence on object volume, motion amplitude, and SBR for
moving targets using an extensive series of phantom scans performed at varying object
volume, motion, and SBR. We validated the model with 24 lung tumors that were imaged
with 4D-CT and PET/CT for radiation therapy simulation and compared IGTVs formed with
our model to IGTVs formed with 6 segmentation methods previously reported in the
literature (Black et al., 2004; Caldwell et al., 2003; Erdi et al., 1997; Nestle et al., 2005;
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Okubo et al., 2008; Paulino et al., 2004). A reliable segmentation technique that
incorporates volume, motion, and SBR into threshold determination could provide radiation
oncologists with a tool to segment tumors whose contrast on cine CT image sets is
insufficient for tumor delineation.

4.3

Methods

4.3.1 Terminology
For clarity, terminology and notation used in this chapter will be summarized in this
section. Many segmentation methods utilize activity concentration (AC) or standardized
uptake value (SUV) measurements in some way. AC is typically in units of Becquerel per
milliliter (Bq/mL). SUV for voxel i is defined in equation ( 7 ) as the AC of the voxel ACi
divided by the injected activity A0 in Bq normalized to patient mass in grams (M). Defined
as such, the units of SUV are grams per milliliter (g/mL). One can make SUV unitless by
normalizing to density of soft tissue, which is assumed equal to that of water (1 g/mL).
Pixel-by-pixel densities are not used to normalize SUV.

HIJ

K
LN
M

(7)

Maximum activity concentration will be denoted ACmax. A threshold value will be
denoted ACn%. For example, 15% of ACmax is described as AC15%. Mean activity

"""""""
concentration, which requires an ROI in which to take the mean, is denoted 
O% which can

be interpreted as “mean activity concentration of voxels above n% of ACmax. All ROIs in this
chapter were formed using seed-based region growing (thresholds were not applied to the
entire image), so all ROIs are closed shapes. Mean activity concentration in background is
"""""""
designated by 
P . ROIs produced from these methods will be denoted similarly. For
example, the IGTV produced by taking all voxels above 15% of ACmax will be indicated

“IGTV15%.” More complex methods will be defined accordingly.
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It is also worthwhile to review the distinction between “GTV” and “IGTV,” as both
will be included in the discussion with reference to the literature. “IGTV” is a term coined
by M. D. Anderson and is not recognized outside the institution. In this chapter, the term
“GTV” will be used when motion was neglected or there was no intent to capture motion.
For example, when a study investigated delineation of gross tumor with a free-breathing
helical CT where no attempt was made to incorporate motion information (whether
through inhale/exhale breath-holds, expanding to ITV, etc.), the gross tumor volume is
“GTV.” IGTV will be used to reference gross tumor volume with a motion envelope
included, in other words, where the intent was to capture motion. Most papers in the
literature explore GTV delineation, not IGTV delineation. In fact, 4 of the 6 segmentation
methods utilized in this study were not originally intended to form IGTVs. It is, however,
our intention to include motion and compare with a motion-inclusive ROI, so all segmented
ROIs in this chapter will be referred to as “IGTV.”

4.3.2 Development of the Regression Model
4.3.2.1 Phantom Scanning
The goal of the phantom scans was to determine the AC threshold on PET
(IGTVPET_n%) which best matched the IGTV defined on cine CT (IGTVCT) for a range of sphere
sizes, motion extents, and SBRs. The best-matched thresholds would then be used to
develop a segmentation model with linear regression techniques.
The NEMA IEC thorax phantom (Data Spectrum, Chapel Hill, NC) was used to form
the regression function. The phantom has 6 spheres of varying size set inside a background
tank. The 6 spheres had inner diameters equal to 10, 13, 17, 22, 28, 37 mm. These spheres
and the background tank were filled to 6 SBRs: 5:1, 10:1, 15:1, 20:1, 30:1, and 50:1. A
sinusoidal motion platform was placed on the flat couch of a General Electric Discovery VCT
64-slice PET/CT scanner (GE Health Care, Waukesha, WI). The phantom was placed on the
motion platform (Figure 4.1) and moved sinusoidally with a range of motion amplitudes (0,
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5, 10, 15, 20, 25, 30 mm peak
peak-to-peak)
peak) and 4 second period. The amplitude and period of
the sinusoidal motion were chosen to represent typical motion extent (Liu et al., 2007;
Stevens et al., 2001) and respiratory frequency (Pan et al., 2006). To summarize, 6 spheres
imaged per motion amplitude per SBR, with 7 amplitudes and 6 SBRs requires 42 PET scans
to capture 252 combinations of the 3 variables.

Figure 4.1:: NEMA IEC thorax phantom on 11-D motion on flat couch of GE Discovery VCT
PET/CT scanner. Reproduced with permission from Riegel et al. (Riegel et al., 2010)
Coincidence data were collected for 18 minutes in 33-D
D mode and were recorded
through list-mode
mode acquisition at each motion extent and SBR. After completion of the scan,
the volume imaging protocol (ViP) replay feature was used to split tthe 18 minute scan into
three 6-minute
minute scans for repeatability. Images were reconstructed using ordered-subsets
ordered
expectation maximization (OSEM
OSEM) reconstruction, 21 subsets and 2 iterations at 50 cm field
of view. Using a 128 × 128 image matrix, voxel sizes were 3.9 by 3.9 by 3.3 mm. PET images
were transferred to a commercial treatment planning system ((Pinnacle3, version 8.1w,
Philips Medical Systems, Milpitas, CA) for delineation of the 6 spheres.
Cine CT was used to capture motion envelopes at each extent to obtain the
reference volume. The
he spheres were drained of liquid while the background tank was kept
filled with water. The scan protocol utilized cine CT at 120 kV, 100 mA, x-ray
ray collimation of
8 × 2.5 mm, CD of 4.8 s, cine interval of 0.4 s, and gantry rotation of 0.4 s. In order to
contour the maximum motion extent, th
the minimum intensity projection was produced
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house software. Because the spheres
directly from the cine CT data (min-IPcine) with in-house
were empty and the background
round tank was full, the min
min-IPcine, which records the lowest pixel
value over the image sequence, captured the motion path of the empty spheres (Figure
4.2). Furthermore, this method allowed us to capture the inner diameter of the moving
sphere, which was consistent with the activity-filled
filled volume imaged by the PET scan. All
min-IPcine images were transferred to the commercial treatment planning system for
contouring.

Figure 4.2:: Minimum intensity projection from cine CT (min-IPcine) for 37 and 28 mm
diameter
ter spheres of NEMA IEC phantom. From left to right: 0, 10, 20, and 30 mm motion
amplitude.

4.3.2.2 Target Delineation
IGTVs of the 6 spheres on the min
min-IPcine images were auto-segmented
segmented using seedseed
based 3-D
D region growing. These ROIs, termed IGTVCT for this chapter, served as the
reference volumes
lumes to which PET threshold volumes would be optimized. A threshold of 425 HU was used to limit the region growing algorithm (Goo et al., 2005; Kemerink et al.,
1998).
The motion-blurred
blurred spheres on PET imaging were segmented by determining ACmax
in each sphere and auto-segmenting
segmenting 10
10-20
20 ROIs at different percentage thresholds (in 1%
intervals) of ACmax using seed
seed-based
based region growing. These ROIs are termed IGTVPET_n%.
Because PET acquisition occurred on different days for each SBR, care was taken to
reposition the phantom on the scanner bed. To further ensure PET/CT registration and
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mitigate the effects of phantom repositioning, the centroids of IGTVPET_n% and IGTVCT
volumes were registered.
When IGTVCT and IGTVPET_n% were contoured for all spheres, motion extents, and
SBRs, the ROIs were converted to mesh surfaces using a software tool in the treatment
planning system. The mesh surfaces were exported from the treatment planning system
and the separation between the surfaces was analyzed by in-house software.
4.3.2.3 Analysis
To assess differences between IGTVCT and each IGTVPET_n%, we developed an
algorithm to measure the separation between two mesh surfaces similar to the method
used by Pevsner et al. which can assess concave volumes (Pevsner et al., 2006). This
method was a modification of the method put forth by Remeijer et al. (Remeijer et al.,
1999) and was recently used by Rietzel et al. to compare GTVs drawn on MIP to the union of
GTVs from 10-phase 4D-CT (Rietzel et al., 2008). Our technique was developed in MATLAB
(Mathworks, Natick, MA) and was termed the “surface separation” algorithm. The main
advantage of the surface separation method over simply comparing volume magnitudes
(Nestle et al., 2005; Park et al., 2008) or concordance (Giraud et al., 2002) is that this
method provides specific geometric information of where the volumes disagree.
Furthermore, this information can be visualized in a polar-azimuthal plot (Figure 4.3).
A brief explanation of the surface separation analysis is provided here. For a more
detailed description please see the Appendix. First, slice-by-slice contours were converted
to a triangular mesh by the treatment planning system (this feature is commonly used in
conjunction with model-based auto-segmentation, but is convenient for our purposes as
well). Triangular meshes were created for the IGTVCT and IGTVPET_n% volumes for all n. In
the treatment planning system, region of interest (ROI) and mesh information are stored in
text files called “plan.roi.” Mesh data are stored in Visualization ToolKit (VTK) format.
These data consist of two matrices: First, 3 columns of x, y, and z coordinates which
represent the vertices of the mesh; Second, 3 columns of indices which specify how the
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vertices are connected to form the triangular mesh surface. Our software extracted this
mesh information to recreate the mesh surface in MATLAB.
The software was designed to compare a “test” volume to a “reference” volume. In
this particular application, IGTVCT was the reference volume and IGTVPET_n% was the test
volume. The surface separation “operator” will be signified by the “|” character in this
chapter. For example, comparing IGTVPET_27% (the test volume) to IGTVCT (the reference
volume) is denoted “IGTV PET_27%|IGTVCT”. Rays were projected from the centroid of the
reference volume at equally-spaced altitudinal and azimuthal angles (in our study, 5°
spacing was used). For each ray, we calculated the intersection of the ray and every plane
defined by the triangles of the mesh surface to “sample” the reference mesh surface. For
each sampling point on the reference mesh, we calculated the closest distance to the test
mesh by projecting the sampling point to the planes defined by the triangles of the test
mesh surface. Our algorithm was validated using a series of low and high resolution
spherical meshes of varying size (Figure 4.3).
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Figure 4.3:: (Top) The test mesh ((red)) is compared with a reference mesh (black) with the
surface separation algorithm. Blue lines represent shortest distances between sampling
points on the reference mesh and the test mesh surface. (Bottom) Deviations are
expressed in terms of altitudinal and azimuthal angles.
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In our study, for each sphere volume, motion extent, and SBR, the surface
separation algorithm was iterated to compare IGTVCT and IGTVPET_n%, a series of meshes
created by different thresholds of ACmax. For each iteration, the deviations between the
surfaces were squared and summed to determine which threshold n% produced the
minimal sum of squared differences between IGTVCT and IGTVPET_n%. The resulting threshold
n% was the “optimal” threshold for that sphere volume, motion, and SBR. The algorithm
was repeated for each of 3 image sets per experimental condition and the average optimal
threshold was used for regression.
Multiple regression was utilized to determine a model f(x,y,z) that best described
the relationship between volume, motion, and SBR (3 independent variables) and optimal
threshold (1 dependent variable). This model was termed the “volume/motion/SBR”
model. We first attempted to fit optimal threshold values normalized to ACmax, but quickly
realized that ACmax was substantially degraded by partial-volume averaging (related to
object size) and motion blur (related to motion extent). The normalization factor of the
dependent variable, therefore, was a function of two independent variables we were fitting
against. In order to avoid unnecessary complication in the regression procedure, we
normalized the threshold AC values to a background measurement. The mean AC in a
spherical ROI at the center of the phantom was used for the background measurement
"""""""
(
P ).

Partial volume averaging and motion blur likewise affected the measurement of SBR.

We therefore used the SBR measurement for the largest sphere (where the effect of partial
volume averaging was minimal) without motion for regression. SBR was defined as the
"""""""
""""""""
ratio of 
QR% and the previously-described P as shown in equation ( 8 ).

 S

"""""""""

TL%
""""""""

U

(8)

SBR was measured 3 times, once on each image set per experimental condition. The
average of the 3 SBR measurements was used for regression. Sphere volume was measured
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on the treatment planning system using the segmented ROIs from the 0 mm motion
condition. Nominal motion values were used in the regression.
We also wanted to examine the relative influence of volume, motion, and SBR on
optimal threshold. For this purpose, typical regression coefficients are unreliable; they have
different units and different scales from each other and therefore cannot be compared. We
can, however, transform the variables such that the mean of each variable is 0 and the
standard deviation is 1 and re-run the regression. The resulting regression coefficients,
often called standardized regression coefficients, allow us to infer relative importance of
each variable (Kim et al., 1981). The transformation is shown in equation ( 9 ), where x is
the unstandardized variable, !V and sx are the mean and standard deviation of the

unstandardized variable respectively, and xstd is the standardized variable. The magnitude
of the standardized coefficients, denoted by βn, represents the relative importance of each
term in the regression function.

!0W'

%+%V
0X

(9)

4.3.3 Application of the Regression Function to Patients
4.3.3.1 Imaging
Lung cancer patients who underwent 4D-CT and PET/CT simulation in the same
imaging session were retrospectively included in the study under an IRB-approved protocol
if the patient demonstrated one or more solid lesions with relatively homogeneous uptake
on PET without invasion into the chest wall or mediastinal regions. PET/CT and 4D-CT
simulations were performed on an 8-slice PET/CT scanner (General Electric Discovery ST,
General Electric Medical System, Waukesha, WI). The 4D-CT protocol used 120 kV, 100 mA,
0.5 s gantry rotation, 0.25 s cine interval, and cine duration equal to 1 average breathing
cycle plus 1 s. For PET imaging, patients were injected with 477 to 740 MBq and PET was
acquired in 2-D mode for 3 minutes per bed position from the base of skull to mid-thigh.
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Attenuation correction was performed with respiratory-averaged CT (Chi et al., 2007; Pan et
al., 2005). Images were reconstructed with OSEM iterative reconstruction utilizing 30
subsets and 2 iterations, with a 3.91 mm FWHM loop filter, 5.45 mm FWHM post filter, and
z-axis filtering applied. Both PET and CT imaging used a 50 cm field-of-view with a 128 ×
128 and 512 × 512 image matrix respectively, producing pixel sizes of 3.9 mm and
approximately 1 mm respectively. PET slice thickness was 3.27 mm and CT slice thickness
was 2.5 mm. PET and 4D-CT images were transferred to treatment planning system for
contouring.
4.3.3.2 Target Delineation
To form the “reference” IGTVCT, the motion envelope was contoured on the MIPcine.
A seed-based 3-D region growing auto-segmentation algorithm was used to minimize
observer variation and bias. As with the phantom scans used in model development, a
threshold of -425 HU was used to limit the region growing algorithm (Goo et al., 2005;
Kemerink et al., 1998). A radiation oncologist reviewed and adjusted the IGTVCT contours if
necessary.

Table 4.1: Tumor delineation methods on PET
Study
Delineation Technique
Caldwell et al. (Caldwell et al., 2003) 15% of ACmax
Okubo et al. (Okubo et al., 2008)
35% of ACmax
Erdi et al. (Erdi et al., 2002)
42% of ACmax
Paulino et al. (Paulino et al., 2004)
SUV = 2.5 g/mL
""""""""
Nestle et al. (Nestle et al., 2005)
15% of 
YR% + BG
Black et al. (Black et al., 2004)
0.307 × SUVmean + 0.588
Riegel et al. (Riegel et al., 2010)
Volume/motion/SBR model
ROI = region of interest
ACmax = maximum activity concentration
ACmean = mean activity concentration
SUV = standardized uptake value
BG = background
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ROI Notation
IGTV15%
IGTV35%
IGTV42%
IGTV2.5
IGTV15%+BG
IGTVSUVmean
IGTVV,M,SBR

IGTVs were delineated on PET data sets based on 6 segmentation methods from the
literature (collectively referred to as IGTVPET). These methods are summarized in Table 4.1.
IGTV15%, IGTV35%, IGTV42%, and IGTV2.5 were all single thresholds of ACmax or SUV (Caldwell et
al., 2003; Erdi et al., 2002; Okubo et al., 2008; Paulino et al., 2004). IGTV15%+BG was more

""""""""
complex, as it was formed by calculating 15% of 
YR% , adding the result to a background
"""""""
measurement, and setting the threshold at this value. As described in Nestle et al., 
P

was measured in a small ROI defined in the adjacent anatomical structure with the highest
background activity (Nestle et al., 2005). Though IGTVSUVmean only requires a measurement
of SUVmean as input for the linear function, the starting threshold required to measure
SUVmean is not specified. The authors address this circular problem by starting at an
arbitrary threshold, taking the mean, (we used """"""""""
HIYR%) and iterating through the

regression function several times, each time producing a new SUVmean for input into the
next iteration (Black et al., 2004). As per the author’s suggestion, we iterated 5 times. All
IGTVs were formed using seed-based region-growing automatic segmentation in the
treatment planning system.
IGTV was contoured using our motion-inclusive model by measuring the tumor
volume, motion, and SBR and plugging them into the model. Tumor volume and motion
were determined by auto-segmenting the end-inspiration and end-expiration phases of the
4D-CT. Volume was measured at end-expiration, and motion was measured as the distance
between the end-inspiration and end-expiration centroids. SBR was calculated by equation
"""""""
( 8 ) where 
P was measured by segmenting the ipsilateral lung, removing any areas of

high uptake (tumors, inflammation, imperfect segmentation near the mediastinum, etc.),
and measuring mean AC in the remaining lung voxels (van Baardwijk et al., 2007). IGTV
produced using the volume/motion/SBR model (IGTVV,M,SBR) was created by seed-based
region-growing auto-segmentation of the PET images. Prior to threshold calculation,
however, a recovery coefficient (described in the next section) was applied to the SBR.
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4.3.3.3 Recovery Coefficient
The measured SBR value was degraded by partial volume averaging (Soret et al.,
2007) and tumor motion (Boucher et al., 2004). Recall that true SBR was used for multiple
regression to develop our model (section 4.3.2.3). We therefore corrected for size and
motion degradation by multiplying the degraded SBR by a recovery coefficient (RC). The RC
""""""""
was developed from the phantom data. 
QR% for each sphere size and motion condition

was compared with the largest stationary sphere, such that the RC for each size and motion

condition was defined as:

S!, Z

""""""""

QR% 26.5,0
""""""""

QR% !, Z

( 10 )

where x is volume in cubic centimeters and y is extent of motion in millimeters. RCs were
averaged over the 3 phantom trials. The largest nominal sphere volume is 26.5 cm3 and “0”
represents the stationary scan condition. Multiple regression was used to fit an RC function
of volume and motion. Recovered SBR is simply the product of the degraded SBR and the
RC for the size and motion of the object of interest.
4.3.3.4 Analysis
The AC thresholds that best matched IGTVCT were determined for each patient in the
same manner as the phantoms. ROIs were segmented on PET images at a range of ACn% at
1% intervals of ACmax. Each threshold volume was compared with IGTVCT using the surface
separation tool. The threshold that produced the minimal sum of squares was considered
the “best fit” threshold. This provided an independent standard to compare against
performance of the segmentation techniques. AC thresholds produced by each of the 7
segmentation methods were correlated with the measured “best fit” AC threshold.
Each IGTVPET was geometrically compared with IGTVCT two ways: First, by measuring
the magnitude of each IGTVPET and IGTVCT volume, and second, by measuring the surface
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separation between each IGTVPET and IGTVCT using the algorithm described in section
4.3.2.3. Using this tool, we calculated the mean surface separation between IGTVCT and
each IGTVPET (IGTVPET|IGTVCT). We were, essentially, comparing radius (via surface
separation) and volume of the IGTVs, similar to the analysis of Nestle et al. in which the
authors calculated the virtual radius of the tumor from the measured volume assuming a
spherical shape (Nestle et al., 2005). IGTVPET volume magnitudes were compared with
IGTVCT for statistically significant differences by log-transforming the data to ensure
normality (Limpert et al., 2001) and performing a paired t-test (α=0.05). Surface separation
for each IGTVPET|IGTVCT pair was compared with IGTVV,M,SBR|IGTVCT using a paired t-test
(α=0.05).
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Figure 4.4:: Transverse, sagittal, and coronal PET images of the 37 mm inner diameter
sphere moving at 20 mm sinusoidal motion amplitude. The green contour represents
IGTVCT derived from cine CT. Purple contours represent IGTVPET_n% at a range of activity
concentration thresholds. The optimal threshold (the threshold that created the purple
ROI most similar to the green ROI) was determined with the surface separation algorithm.
Reproduced with permission from Riegel et al. (Riegel et al., 2010)
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4.4

Results

4.4.1 Volume/Motion/SBR Segmentation Model
PET images for each of the 252 combinations of volume, motion, and SBR were
segmented as described in section 4.3.2.2. An example of these contours is shown in Figure
4.4. Approximately 20 percentage thresholds were contoured for each
volume/motion/SBR combination, resulting in approximately 5000 ROIs to analyze with the
surface separation algorithm. Optimal thresholds were unable to be determined for 5
volume/motion combinations at SBR of 5:1 (1.2 cm3 at 30 mm motion, 0.5 cm3 at 15-30 mm
motion). The substantial motion blurring caused the spheres to be indiscernible from
background. Nominal sphere volume and SBR versus measured values used for regression
are shown in Table 4.2. Note that ROIs segmented with a -425 HU threshold are within ±1
mm (approximately 1 CT pixel) of the sphere’s true inner radius.

Table 4.2: Nominal and actual volumes and SBRs
Volume (cm3)
SBR (unitless)
Nominal Measured Nominal Measured
26.5
28.6
5
4.33 ± 0.02
11.5
12.7
10
8.12 ± 0.25
5.6
6.4
15
14.88 ± 0.22
2.6
3.1
20
19.91 ± 0.73
1.2
1.4
30
28.88 ± 1.40
0.5
0.7
50
52.15 ± 1.95
SBR = source-to-background, measured in the largest stationary
sphere
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Figure 4.5:: Optimal thresholds (normalized to background) versus motion, source-tobackground (SBR), and sphere volume. Volume is denoted by the different colors and
symbols shown in the legend (which lists nominal sphere diameters). Error bars represent
1 standard deviation. Reproduced with permission from Riegel et al. (Riegel et al., 2010)
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Figure 4.5 is a 3-D scatter plot of the optimal thresholds for each of the 252
combinations of volume, motion, and SBR. Since our data is four-dimensional and is
therefore difficult to visualize, motion, SBR, and optimal threshold were placed on separate
axes, with sphere inner diameter represented by different symbols and color for each value.
There are clear patterns to the data and isolating the patterns by keeping one variable
constant is helpful to suggest terms for the regression model. The relationship of optimal
threshold with SBR, for example, is close to linear (Figure 4.6). Optimal threshold versus
motion and volume, however, are more complicated (Figure 4.7 and Figure 4.8). After
trying several combinations of functions that were physically appropriate to the phenomena
(quadratic functions, for example, were not considered because there is no reason to
expect maxima or minima, and therefore do not make sense physically), we settled on the
model shown in equation ( 11 ). Threshold normalized to background is denoted by w, x is
volume in cubic centimeters, y is motion in millimeters, z is SBR (unitless), and Bn are the
regression coefficients.

Optimal thresholds vs. SBR: Motion = 0 mm
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Figure 4.6: Optimal threshold versus source-to-background for stationary spheres. Each
line represents a different sphere diameter as denoted in the legend. Note the linear
nature of the relationship. Error bars are 1 standard deviation (3 measurements).
Reproduced with permission from Riegel et al. (Riegel et al., 2010)
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Optimal threshold vs. Motion: SBR = 19.9
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Figure 4.7: Optimal threshold versus motion for source-to-background = 19.9. Each line
represents a sphere diameter as shown in the legend. Error bars are 1 standard deviation
(3 measurements). Reproduced with permission from Riegel et al. (Riegel et al., 2010)

Optimal threshold vs. Volume: SBR = 19.9
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Figure 4.8: Optimal threshold versus volume for source-to-background = 19.9. Each line
represents motion extent (0 mm to 30 mm). Error bars are 1 standard deviation (3
measurements). Reproduced with permission from Riegel et al. (Riegel et al., 2010)

80

lna

-!

-N
b

-N
g eZ b lnc

?

f?

Z

-N
b

h xZ

?

-N
b

b lnc

?

Y

?

d e!

-N
b lnc

f?

( 11 )

There are a few noteworthy aspects of this equation. First, because the residuals
increased with increasing SBR, we took the natural logarithm of the threshold values w. We
therefore took the natural log of SBR in the model to maintain the previously linear
relationship with optimal threshold. For volume, the choice of cube root is not entirely
surprising because radius is proportional to the cube root of volume. For motion, we
originally tried a logarithmic function. We measured optimal threshold, however, at a
motion extent of 0 mm and log is undefined at zero. A cube root, therefore, was chosen
because it behaves similarly to natural log but is defined at zero. The second three terms in
the equation are interaction terms and were included in the model because we found their
inclusion created a substantially better fit to the data.
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The volume/motion/SBR model with regression-determined coefficients is shown in
equation ( 12 ). This function produced an R2 value of 0.96 and an adjusted R2 value (which
accounted for increasing R2 due to additional terms in the fitting function) of 0.96. Several
surfaces of the regression function (because the function is a family of surfaces) are shown
in Figure 4.9.
The standardized regression coefficients, often denoted as βn, are listed in Table 4.3.
Of the 3 independent variables, SBR was the most influential (β3 = 1.0606), followed by
motion (β2 = 0.2114), then volume (β1 = 0.0841). Both interaction terms with SBR, however,
were more influential than motion and volume alone.
81

Figure 4.9:: Surfaces of regressi
regression function defined in equation ( 12 ).. Each of the 4
surfaces displayed
splayed is calculated for spheres of inner diameter 10, 17, 28, and 37 mm.
Reproduced with permission from Riegel et al. (Riegel et al., 2010)

Table 4.3:: Regression coefficients for model in equation ( 11 ).
Variable
Bn
βn
Volume
0.0634
0.0841
Motion
0.12
0.21
SBR
0.7327
1.0606
Volume • SBR
0.0597
0.275
Motion • SBR
-0.12
-0.73
Volume • Motion
-0.025
-0.110
Constant
-0.9504
-0.0321
Bn = unstandardized regression coefficients
βn = standardized regression coefficients
“•” denotes interaction term
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4.4.2 Application to Patient Studies
The RC function developed from phantom data (R2=0.95) is shown in equation ( 13 ).
Again, x is volume in cubic centimeters and y is motion extent in millimeters. Volume and
motion measurements were plugged into equation ( 13 ), and the degraded SBR and RC
were multiplied to obtain the recovered SBR.
S!, Z

0.199! +- ? 0.014Z ? 0.073! +- Z ? 0.8839

( 13 )

Twenty-four tumors (23 patients) scanned from May 2004 to February 2009 fit our
criteria, were adequately registered, and were included in the analysis. IGTV15% could not

be segmented for 6 tumors because -g% fell below background AC. Similarly, IGTV2.5

could not be segmented for 2 tumors for the same reason. As such, t-tests were performed
with paired values, limiting the sample to 18 and 22 tumors respectively.
Volume, motion, and SBR measurements for the 24 tumors as well as threshold
values calculated from the volume/motion/SBR model are shown in Table 4.4. Linear
correlations (y = mx+b) of the measured “best fit” threshold value and the threshold

predicted by each segmentation technique for every patient are shown in Figure 4.10. The
correlation of IGTVV,M,SBR thresholds with measured values has the slope closest to 1 (m =
0.8991) implying good correlation of predicted with best-fit values, the y-intercept closest
to 0 (b = 1.3963) implying little systematic over- or underestimation, and the highest R2
value (R2 = 0.8577).

83

Table 4.4: Volume, motion, and source-to-background characteristics of 24 lung tumors,
with model-produced threshold
Volume Motion
Corrected SBR
Threshold
Tumor
(cm3)
(mm)
1
21.1
10.8
30.07
4.3685
2
15.3
7.8
26.37
4.1071
3
1.1
10.3
7.21
1.4395
4
0.8
6.2
48.19
4.3495
5
1.0
6.6
19.63
2.6316
6
28.0
1.5
13.47
3.6915
7
2.5
13.6
18.38
2.3723
8
1.5
2.4
25.08
3.6546
9
0.7
4.6
20.17
2.7718
10
0.6
2.2
13.05
2.3129
11
13.6
1.0
39.76
7.6571
12
1.1
8.0
5.49
1.2723
13
10.3
8.6
25.90
3.7288
14
0.4
8.8
13.41
1.9457
15
3.6
4.0
7.87
1.7821
16
2.2
15.0
8.57
1.5572
17
4.8
3.1
9.19
2.0621
18
2.7
2.7
25.17
3.8271
19
0.7
1.5
20.59
3.2432
20
1.6
6.3
29.31
3.4625
21
1.5
2.7
14.60
2.5703
22
5.2
0.6
17.73
3.7687
23
0.1
1.0
11.52
2.1201
24
0.5
5.1
23.55
2.9347
SBR = source-to-background ratio
Threshold is normalized to background and is therefore unitless.
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Figure 4.10: Correlation between predicted
threshold values and measured optimal
threshold values for each segmentation
method. Best-fit
fit lines, their equations, and
2
R values of the fit are shown in each plot.

GTVs contoured for each delineation method for tumor 13, a
Figure 4.11 shows IGTVs
typical case. IGTVCT is denoted by the thick red line. For this patient, the volume magnitude
of IGTVV,M,SBR most accurately matched IGTVCT (-1.1%) followed by IGTV15% (-10.1%). Surface
separation was less than 2 mm for IGTV15%, IGTV2.5, IGTV15%+BG, IGTVSUVmean, and IGTVV,M,SBR.

Figure 4.11:: (A) Transverse, (B) sagittal, and (C) coronal PET/CT images of tumor 13 with
internal gross tumor volume ((IGTV) contours. PET is displayed with a “thermal” colormap.
IGTVCT, shown in red, was delineated on MIPcine. Other IGTVs
GTVs were delineated on PET
using methods described in Table 4.1.. The contour from the volume/motion/SBR model
(IGTVV,M,SBR) is shown in green.

86

Figure 4.12 provides another patient example, tumor 1. For this patient, the volume
magnitude of IGTVV,M,SBR most accurately matched IGTVCT (-11.0%)
11.0%) followed by IGTV2.5
(-12.2%). Surface separation
tion was again less than 2 mm for IGTV15%, IGTV2.5, IGTV15%+BG,
IGTVSUVmean, and IGTVV,M,SBR. IGTVV,M,SBR had the lowest mean surface separation at 1 mm.

sagittal, and (C) coronal PET/CT images of tumor 1 with
Figure 4.12:: (A) Transverse, (B) sagittal
internal gross tumor volume ((IGTV) contours. PET is displayed with a “thermal” colormap.
IGTVCT, shown in red, was delineated on MIPcine. Other IGTVs
GTVs were delineated on PET
using methods described in Table 4.1.. The contour from the volume/motion/SBR model
(IGTVV,M,SBR) is shown in green.
Volume and surface separation analyses for all patients are summarized in Table 4.5
and illustrated in Figure 4.13
13 (volume analysis) and Figure 4.14 (surface separation analysis).
analysis)
Of the 7 segmentation
on methods, 6 underestimated mean volume compared to the motionmotion
inclusive IGTVCT. IGTV15%, IGTV
GTV35%, IGTV42%, and IGTV2.5 were significantly smaller than
IGTVCT. IGTV15%+BG, IGTVSUVmean, and IGTVV,M,SBR volumes were not significantly different
from IGTVCT. IGTVV,M,SBR produced the smallest difference with IGTVCT (-5.15%).
5.15%). Note that
Figure 4.13 shows IGTV2.5 slightly closer to IGTVCT than IGTV15%+BG, which was not
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significantly different than IGTVCT. Though this appears contradictory, IGTVCT displayed on
the graph is the average of all patients whereas the statistical comparison with IGTV2.5 used
only the tumors that could be contoured (in this case, N=22). The same is true for IGTV15%
(N=18).
Mean surface separation (Figure 4.14) produced results consistent with the volume
comparison. IGTV15%|IGTVCT, IGTV35%|IGTVCT, IGTV42%|IGTVCT, and IGTV2.5|IGTVCT produced
surface separations significantly larger than IGTVV,M,SBR|IGTVCT. IGTV15%+BG|IGTVCT and
IGTVSUVmean|IGTVCT were not significantly different from IGTVV,M,SBR|IGTVCT.

Table 4.5: Comparison of IGTVPET with IGTVCT for different segmentation methods
Notation

Volume ±
SEM (cm3)

p

(IGTVPETIGTVCT) ±
SEM

Mean Surface
Percent
Separation
p
Difference
(mm)
(%)
+10.7%
1.9±0.7
0.02
-50.1%
2.4±0.8
<0.01
-62.5%
3.0±1.1
<0.01
-22.3%
2.4±1.7
0.04
-23.6%
1.7±0.5
0.44
-15.7%
1.6±0.5
0.98
-5.15%
1.6±0.5
--------Non-significance p-values are in red.

IGTV15%*
10.93±2.71
0.01
+1.05±0.89
IGTV35%
4.15±0.99
<0.01
-4.17±1.24
IGTV42%
3.12±3.93
<0.01
-5.21±1.38
IGTV2.5†
6.93±2.14
<0.01
-1.99±0.73
IGTV15%+BG
6.36±1.67
0.14
-1.96±0.60
IGTVSUVmean
7.02±1.67
0.33
-1.30±0.65
IGTVV,M,SBR
7.89±1.76
0.39
-0.43±0.55
IGTVCT
8.32±2.16
----Statistically significant differences are in green print.
SEM = standard error of the mean
*N = 18. Statistics were calculated using paired values.
†N = 22. Statistics were calculated using paired values.
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Figure 4.13: Volumes (in cubic centimeters) of IGTVPET and IGTVCT. Error bars represent
standard error of the mean (N = 24 tumors for IGTV35%, IGTV42%, IGTV15%+BG, IGTVSUVmean,
IGTVV,M,SBR, N = 22 for IGTV2.5, N = 18 for IGTV15%). p-values are shown with each column
(green = significant, red = non-significant).
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Figure 4.14: Surface separation (in millimeters) between IGTVPET and IGTVCT. Error bars
represent standard error of the mean (N = 24 tumors for IGTV35%, IGTV42%, IGTV15%+BG,
IGTVSUVmean, IGTVV,M,SBR, N = 22 for IGTV2.5, N = 18 for IGTV15%). p-values are shown with
each column (green = significant, red = non-significant).
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4.5

Discussion
We successfully developed an expression for optimal AC threshold as a function of

object volume, motion, and SBR. The volume/motion/SBR model, described in equation
( 12 ), fit the data well (adjusted R2 = 0.96). By determining standardized regression
coefficients, we found that SBR was the most influential variable in the model. In applying
this model to 24 lung tumors, we found the volume/motion/SBR model generated an
IGTVPET that accurately matched IGTVCT in volume magnitude (mean of 5.15%
underestimation) and surface separation (mean of 1.6 mm). The volume/motion/SBR
model produced the smallest volume differences and tied for the smallest surface
separation compared with 6 other segmentation techniques.
This investigation is the most comprehensive examination of threshold-based
segmentation of PET imaging of moving targets to date. It is the first to investigate the
relationship between motion, size, and SBR for large ranges of SBR (5:1 to 50:1) and motion
(0-30 mm), and the first to use the surface separation algorithm to determine optimal
threshold volume. Several studies have explored elements of the current work, but not to
the same depth. Yaremko et al. determined optimal thresholds for moving and static
spheres in air, sizes ranging from 0.56 mL to 57.37 mL with 25 mm motion amplitude
(Yaremko et al., 2005). Caldwell et al. investigated feasibility of using PET to delineate ITV
by assessing PET images of 3 moving spheres (inner diameters = 1.3, 2.9, 6.6 cm) at 3
motion amplitudes (7, 16, 27 mm). The authors did not, however, determine optimal
thresholds for each experimental condition but qualitatively found 15% of ACmax produced
an adequate ITV (Caldwell et al., 2003). Black et al. examined the influence of size and,
indirectly, SBR by developing a linear function of mean SUV, but motion was not included
(Black et al., 2004).
There are several recent studies of moving phantoms that are similar to the modeldevelopment portion of this investigation. Park et al. examine the effects of target size,
motion, and background activity on optimal thresholds in a phantom (Park et al., 2008).
The authors use the NEMA IEC phantom (sphere diameters identical to the current work),
sinusoidal motion with amplitudes of 0, 10, 20 mm (adjusted with an exponential shaping
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parameter), and SBRs of 4.0, 8.3, and infinite (no background) to determine optimal
thresholds for these varying conditions. After re-normalizing the threshold values in Figure
4.5 to ACmax for comparison, we found that the optimal thresholds in our study were
generally lower than those determined by Park et al.
One significant difference between the two studies was the purpose of determining
optimal thresholds. Park et al. intended to show the difficulty of obtaining the “true target
volume” without gated (4-D) PET, which required comparing PET volumes to the known
sphere volume, i.e. the stationary sphere. This explains the large difference in thresholds at
2 cm motion (90% in Park et al. vs. 18% in the current study for the smallest sphere with
SBR = 8) (Park et al., 2008). The goal of this chapter was to match PET threshold volumes
with motion-inclusive IGTV often used in 4D-CT-based simulation, not the volume of the
spheres themselves. Our values, however, were lower for the stationary spheres as well,
especially for the smallest sphere (75% in Park et al. vs. 40% in the current study with SBR =
8). This difference can most likely be explained by the fact that Park et al. compared
volume magnitudes and we compared surfaces. Volume was estimated by summing the
number of voxels above the threshold and multiplying by voxel volume, which, for Park et
al., was 4.7 × 4.7 × 3.27 mm. The width of one voxel was almost one half the inner diameter
of the smallest sphere, which causes partial volume averaging and inaccurate calculation of
the volume. The surface separation algorithm essentially measures between meshes
interpolated from the voxel-based contours. Though not technically higher resolution, the
interpolated meshes give us a finer estimation of the best-fit threshold volume.
Brambilla et al. investigated target volume delineation in the NEMA IEC thorax
phantom as a function of several variables, including SBR, sphere diameter, injected activity,
and emission scan duration (motion was not examined) (Brambilla et al., 2008). Using
multiple linear regression and standardized regression coefficients, the authors found that
for sphere diameters less than 10 mm (additional microspheres of inner diameter 4.1, 4.7,
6.5, and 8.1 mm were added to the phantom for analysis), sphere diameter and SBR were
significant predictors of optimal target threshold (as a percentage of ACmax). SBR
dependence, however, could be neglected with little effect on optimal threshold to a first
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approximation. For sphere diameters greater than 10 mm, again sphere diameter and SBR
were significant predictors of optimal target threshold, but the opposite relationship
between the two was observed: Sphere diameter was less significant and, to a first
approximation, could be neglected. Injected activity and emission scan duration were not
included in the current work because Brambilla et al. found both to be non-significant
predictors of optimal threshold.
The multiple regression techniques used in the current study are similar to those
used in Brambilla et al. In selecting their regression model, the authors determined from
previous studies that optimal threshold normalized to ACmax is related to 1/SBR (Brambilla
et al., 2008). In the present study, we found a nearly linear relationship between SBR and
optimal threshold normalized to background. These findings are consistent: An inverse
relationship between SBR and threshold normalized to “signal” is equivalent to a linear
relationship between SBR and threshold normalized to “background.” Brambilla et al. also
used standardized regression coefficients in their study and found that SBR is the most
influential variable for sphere diameters greater than 10 mm, which is consistent with the
findings of the current study.
Okubo et al. used the NEMA IEC body phantom on a motion platform to examine
optimal thresholds of moving spheres. In a stationary phantom at SBRs of 10:1, 15:1, and
20:1, the authors found 35% of ACmax was a reasonable threshold (Okubo et al., 2008) after
excluding the smaller spheres (inner diameter 10-17 mm) due to partial volume averaging.
The 35% of ACmax threshold was applied to PET images of moving spheres at an SBR of 20:1.
Motion was characterized as sinusoidal with a 4-sec period to 10, 20, and 30 mm
amplitudes (peak-to-peak). The authors found that a 35% threshold overestimated actual
sphere size in the sagittal plane and underestimated the actual sphere size in the axial
plane. The extent in the sagittal plane, however, was smaller than the ideal IGTV. For
comparison, we segmented the 28 mm inner diameter sphere, at 30 mm motion extent,
and SBR = 19.9, at 35% of ACmax and compared with the stationary sphere (Figure 4.15).
Axial extent was underestimated and sagittal extent was overestimated compared with the
stationary sphere, consistent with the findings of Okubo et al. The motion envelope
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(IGTVCT), however, was underestimated in both axial and sagittal directions, suggesting that
35% of ACmax is too high a threshold to capture the entire extent of motion.

Figure 4.15: Reference volume for stationary sphere (black mesh, inner diameter = 28
mm) compared with 35% maximum activity concentration of same volume sphere at 30
mm motion extent and source-to-background = 19.9 (red mesh). Note that the 35%
threshold underestimates the axial and overestimates the sagittal extent of the sphere,
but underestimates the full motion envelope of the tumor. Reproduced with permission
from Riegel et al. (Riegel et al., 2010)
Several contouring methods, including those of Okubo et al. and Caldwell et al.
discussed above, were applied to 24 lung tumors along with our volume/motion/SBR
model. Our patient validation study is similar to a study by Nestle et al. which focused on a
comparison of PET segmentation techniques for NSCLC (Nestle et al., 2005) but there are
several key differences. First, in the previous study, PET was acquired using a standalone
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PET scanner with 137Cs transmission scanning for attenuation correction. The current study
utilizes an integrated PET/CT scanner with RACT attenuation correction. Second, the
previous study contained 5 tumors able to be fully delineated on CT, whereas 24 tumors in
our study were delineated on CT. Third, free-breathing CT was used to delineate the GTV in
the previous study (which required additional coregistration because the PET and CT were
not hardware-fused) and a margin was applied to account for breathing motion (1.5 mm
lateral, 2 mm anterior-posterior, 3 mm superior-inferior). We explicitly determined the
“motion envelope” of the tumor (IGTV) using 4D-CT.
The PET segmentation methods used in this study can be roughly split into two
groups: The “first order” methods, which utilize a single threshold of activity concentration
or SUV to form IGTV, and the “second order” methods, which incorporate additional
variables into threshold determination. IGTV15%, IGTV35%, IGTV42%, and IGTV2.5 fall into the
first category, while IGTV15%+BG, IGTVSUVmean, and IGTVV,M,SBR fall into the second. Our
analysis suggests there are advantages to using more complex methods. IGTVV,M,SBR,
IGTV15%+BG, and IGTVSUVmean produced smaller surface separations than all first order
methods and volume magnitude differences smaller than all but 1 first order method
(IGTV15%) when compared with IGTVCT. Though IGTV15% performed relatively well in the
volumetric analysis (the percent difference with CT was second smallest), 6 tumors (25%)
were unable to be contoured because 15% of ACmax was below the background activity
concentration in those patients. The paired t-test with the remaining pairs showed IGTV15%
being significantly larger than IGTVCT and the inability to contour IGTV15% in high background
limits the applicability of such a method.
Of the second order techniques, IGTVV,M,SBR produced the smallest average volume
difference with IGTVCT (-5.15%) and tied IGTVSUVmean for the smallest average surface
separation (1.6 mm). The differences, however, were not statistically significant. The
second order methods had the smallest standard deviations in both volume difference and
surface separation, suggesting they are more adaptable and more consistently delineate
tumor over a sample of patients with varying characteristics. IGTVV,M,SBR demonstrated the
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best adaptability by producing the lowest standard error of the mean in volume difference
from CT.
The lack of statistical superiority of our segmentation technique (that includes
motion) over the other second-order methods (that neglect motion) may indicate the
importance of SBR relative to the other variables in the segmentation procedure in a clinical
setting. Recall that we demonstrated SBR was the most influential variable in the model via
the standardized regression coefficients. The fact that both IGTV15%+BG and IGTVSUVmean
explicitly or implicitly account for SBR (the former by simply forming a threshold above a
background measurement and the latter by using SUVmean, a value normalized to injected
activity divided by patient weight which is essentially “background” if one assumes the
patient is uniform) and both perform nearly as well as a method that accounts for size,
motion, and SBR seems to suggest that considering SBR in segmentation is essential and the
other variables could be neglected. Our results, however, indicate that including size and
motion in the segmentation technique can further increase the accuracy of the PET contour
when compared with CT, though the improvement was not statistically significant.
The current manifestation of the volume/motion/SBR model represents a first
approximation to modeling real moving tumors and there are several ways the model can
be improved. The measurement of SBR, and particularly the measurement of background,
is evidently critical for segmentation and the various factors that affect SBR should be
further investigated. The selection of the background ROI for tumors bordering two tissues
with different uptake such as lung and chest wall, for example, should be evaluated. Since
the model is normalized to background, the selection of background ROI can substantially
affect the resulting threshold. The size- and motion-dependent recovery coefficient to
restore degraded SBR could also be further refined. Additionally, several assumptions were
made in the development of the volume/motion/SBR model that should be explored
further: First, the model was developed using one-dimensional sinusoidal motion, which is
obviously not the case for many lung tumors (Boldea et al., 2008; Mageras et al., 2004). An
asymmetric breathing pattern may be more appropriate (Lujan et al., 1999). Second, the
model was developed with spherical objects; tumors with spiculations or substantial
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asymmetry may not conform to the model. Third, we assumed that motion during the 4DCT exam was essentially the same as motion during the PET exam. Motion patterns,
including amplitude, frequency, and baseline position, can change over time (Nehmeh et al.,
2004) leading to mismatching motion envelopes or misregistration. Fourth, the model was
developed assuming homogeneous uptake, which is a reasonable assumption for smaller
tumors, but not for larger tumors where heterogeneity, hypoxia, or necrosis often occur.
The impact of AC heterogeneity on the volume/motion/SBR model should be evaluated.
Nevertheless, the volume/motion/SBR model has produced promising results and
could be fine-tuned to produce more accurate contours. Though the model itself is
somewhat complex, application is relatively simple. Only 4 measurements are required:

"""""""
""""""""
Tumor volume, motion extent, 
QR% of the tumor, and P . First order techniques may

be simpler, but the findings of Biehl et al. suggest that a single threshold is inappropriate for
target delineation (Biehl et al., 2006) and, given the results of our validation, we must
concur. Nestle et al. found that 40% threshold of ACmax underestimates GTVCT with a
population-based expansion to account for motion (Nestle et al., 2005). We had similar
findings for both IGTV42% and IGTV35% when compared with a motion envelope explicitly
determined on 4D-CT (as illustrated qualitatively in Figure 4.15 for IGTV35% and
quantitatively in Figure 4.13 and Figure 4.14). Sura et al. found high local failure rates when
using PET to visually aid delineation of GTV (Sura et al., 2008), so caution must be exercised
when using methods which substantially underestimate gross tumor.
Segmentation by threshold is a common method of target delineation with PET, but
gradient methods have been investigated as well. Drever et al. compared threshold-based
segmentation with Sobel edge-detection and a watershed technique (Drever et al., 2007).
Sobel edge-detection operates by finding the maximum gradient values in the image and
the watershed technique combines edge detection and region-growing (Drever et al., 2007).
The authors found that both gradient techniques failed to accurately segment stationary
targets in a phantom and that a threshold-based technique was most successful. Though
gradient segmentation is beyond the scope of this work, exploration of gradient-based
segmentation is important and should be pursued in future studies. For moving lung
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tumors, however, we anticipate that a gradient-based approach will be problematic.
Motion blur substantially decreases the AC gradient in the direction of motion, creating a
situation where the edge of the tumor produces a high gradient in planes perpendicular to
motion but a low gradient in planes parallel to motion. A single gradient threshold may be
inadequate.

4.6

Conclusions
A segmentation model for moving lung lesions in PET was developed that

incorporates tumor volume, motion, and SBR into determination of optimal activity
concentration threshold (volume/motion/SBR model). The model, calibrated with an
extensive series of phantom scans at varying size, motion, and SBR, was applied to 24 lung
tumors to form IGTVs. These IGTVs, as well as IGTVs generated from 6 segmentation
methods published in the literature, were compared with IGTV defined on cine CT. The
volume/motion/SBR model produced IGTVs that correlated well with IGTV defined on cine
CT. Segmentation techniques that used a single threshold produced significantly different
IGTVs than the reference CT.
One significant objection to the clinical validation of the volume/motion/SBR model
with respect to the over-arching purpose of this dissertation is the use of 4D-CT to
determine motion extent. Recall that a primary motivation for incorporating PET into
treatment planning in this work was to avoid using 4D-CT for complicated tumors.
Measuring motion with 4D-CT defeats this purpose. We have shown in Chapter 2 ,
however, that substantial motion information can be gleaned from MIPcine and RACTcine
(image sets processed directly from cine CT), so it is probable that estimates of motion
extent could be made with cine CT image sets.
The final chapter combines elements of Chapter 2 and Chapter 4 to contour more
complex tumors.
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Chapter 5 FEASIBILITY OF TARGET DELINEATION OF STAGE III NON-SMALL CELL LUNG
CANCER WITH CINE PET/CT

5.1

Introduction
We have, thus far, focused on early stage lung cancer. We demonstrated the utility

of contouring stage I NSCLC with MIPcine and RACTcine in Chapter 2. We developed and
validated a motion-inclusive PET contouring technique for relatively simple lesions in
Chapter 4. In the final chapter, we assess the feasibility of combining these techniques to
contour locally advanced NSCLC with “cine PET/CT” imaging.
Ultimately, application of this contouring technique to stage III NSCLC would impact
the greatest number of patients because a combination of chemotherapy and radiation
therapy is a standard of care for stage III NSCLC (along with surgical resection for stage IIIA).
There are several differences between stage I and stage III NSCLC, including tumor size,
shape, uptake heterogeneity in PET imaging, and nodal involvement, which make applying
the cine PET/CT contouring technique non-trivial. These different aspects of stage III
disease were not considered during development of the volume/motion/SBR segmentation
model. The largest sphere volume, for example, was approximately 27 cm3, whereas many
stage III GTVs can be greater than 100 cm3. Extrapolation from the model may be
necessary. Such differences may cause problems when the model is applied to more
complex cases.

5.2

Purpose
The purpose of this final study was to explore the feasibility of using PET together

with MIPcine and RACTcine for target delineation of stage III NSCLC by qualitatively assessing
target volumes formed by the PET-based volume/motion/SBR model in stage III NSCLC.
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5.3

Methods
Five patients were included in the feasibility study. Four patients had stage III NSCLC

and each underwent 4D-CT and PET/CT as part of their treatment simulation. One patient
had stage I NSCLC. The patient with stage I NSCLC was previously contoured in Chapter 2 as
“patient 26” and was 1 of 3 patients with a tumor near the diaphragm who demonstrated
substantial differences between contouring on cine CT image sets and 4D-CT. The patient
did not receive a PET/CT at time of simulation but did receive a diagnostic PET/CT two
weeks prior which was used for the feasibility study.

Table 5.1: Patients for cine PET/CT feasibility study
Patient

Stage

T

N

M

Volume
(cm3)
10.7
215.0
5.8
20.0
86.3

1
IA
1 0
0
2
IIIB
3 3
0
3
IIIB
4 0
0
4
IIIA
3 1
0
5
IIIB
4 2
0
T = tumor grade based on tumor size
N = regional nodal status
M = distant metastasis
SBR = source-to-background ratio
Tx = Treatment modality
SBRT = stereotactic body radiation therapy
IMRT = intensity modulated radiation therapy

Motion
(mm)
17.8
8.1
2.9
8.9
1.0

Corrected
SBR
23.2
25.0
17.7
25.4
64.7

Tx
SBRT
IMRT
SBRT
PROTON
IMRT

Tumor volume and motion were estimated using 4D-CT. If volumes could not be
adequately defined using CT alone, volume estimates were made with rough threshold
""""""""
"""""""
segmentation of PET. 
QR% was measured as described in Chapter 4 and P was
measured by manually drawing an ROI in the lung and taking the mean activity
"""""""
""""""""
concentration. Volume, motion, 
QR% , and P served as input for the

volume/motion/SBR model. Threshold calculations were performed on a simple
spreadsheet (Excel, Microsoft, Inc., Redmond, WA), which included the recovery coefficient
(Figure 5.1). IGTVPET formed from volume/motion/SBR thresholds were applied and
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qualitatively compared with fused MIPcine imaging to assess feasibility of using the model to
contour in tandem with CT imaging. In particular, we looked for concordance of IGTVPET
with high contrast tumor/lung boundaries on CT.

Figure 5.1: Microsoft Excel spreadsheet used to calculate thresholds using
volume/motion/SBR model.
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5.4

Results

5.4.1 Patient 1
This patient is the only stage I NSCLC patient and was contoured in Chapter 2 as
patient #26. The PET data set, acquired two weeks prior to 4D-CT simulation, was manually
registered to the tumor. The fused PET/CT data set, along with volume/motion/SBR model
contour, is shown in Figure 5.2. Note the excellent agreement between anterior, posterior,
and superior borders of the model-produced threshold and the MIP data set. The inferior
border is well-described by the volume/motion/SBR model threshold. It is difficult,
however, to say for certain whether or not the model is performing well because PET and
CT were acquired on different days and there is no guarantee the patient was breathing
similarly from day to day. The coincidence of the contour with the CT data set, however, is
striking.

Figure 5.2: Sagittal PET/CT data set and volume/motion/SBR contour (green line) for
patient 1. For this particular patient, PET was performed prior to 4D-CT simulation and
was manually registered to the maximum intensity projection.
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5.4.2 Patient 2
The primary in patient 2 was a large tumor adjacent to the chest wall and aorta. The
tumor demonstrated significant AC heterogeneities, which contributed to an
underestimated tumor boundary compared with CT (green contour, Figure 5.3). In this

case, QR% produced a mean value too high to segment the tumor. Manually drawing an

ROI and taking the mean within the tumor produced a better result (blue contour), but the
maximum motion extent is still underestimated.

Figure 5.3: Coronal PET/CT data set and volume/motion/SBR contours for patient 2.
"""""""""
Green line represents contour when op
qr% is used in volume/motion/SBR model. Blue
line represents contour when mean AC in manually drawn contour in middle of tumor is
used in volume/motion/SBR model.
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5.4.3 Patient 3
This patient had two lesions, one of which was invading the anterior chest wall and
demonstrated 3 mm motion in the anterior-posterior direction. The result was a masking of
the anterior extent of the tumor by the moving chest wall. We applied the model to this
lesion and obtained the contour shown in Figure 5.4. Note that the posterior extent is
slightly overestimated by the model, which may suggest overestimation in the anterior
direction. There is, however, an asymmetric blur to the PET activity concentration gradient
that can be explained by the asymmetric breathing pattern observed when scrolling
through the 4D-CT phase imaging. The tumor spends more time in the posterior part of the
motion envelope, resulting in sharper AC gradients on the posterior edge. For this patient,
"""""""
we obtained a better result using 
P in the chest wall rather than the lung.

Figure 5.4: Sagittal PET/CT data set and volume/motion/SBR contour (green line) for
patient 3.
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5.4.4 Patient 4
The tumor in patient 4 demonstrates substantial mediastinal involvement.
involvement The
resulting volume/motion/SBR threshold volume correlates well with the lateral border on
CT and provides a good example of the ability of PET to distinguish between malignant
tissue and atelectasis (which was noted in the n
nuclear
uclear medicine report of the PET/CT scan).
PET/CT data set and threshold
ld contours are shown in Figure 5.5.

Figure 5.5:: Coronal (left) and transverse (right) PET/CT data set and volume/motion/SBR
contour (green line) for patient 4. Note the atelectasis present in the left upper lobe on
the transverse CT image.
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5.4.5 Patient 5
A similar case to patient 4, the tumor in patient 5 demonstrates substantial
mediastinal involvement with more heterogeneity in the metabolic uptake of FDG. Again,
the volume/motion/SBR model produces a volume that agrees well with the lateral border
on CT. The superior-anterior
anterior border also matc
matches well. PET/CT data set and threshold
contours are shown in Figure 5.6.

Figure 5.6:: Sagittal (left) and transverse (right) PET/CT data set and volume/motion/SBR
contour (green line) for patient 5.

5.5

Discussion
The current chapter explored the feasibility of applying the volume/motion/SBR

model,, which was developed using phantom scans and validated with reasonably simple
tumors, to more complicated stage III NSCLC tumors. The results were mixed: The
volume/motion/SBR model produced qualitatively good thresholds for some tumors
(patients 1, 4, and 5) but not in others (patients 2 and 3). Obviously, further study will be
needed to validate the use of the volume/motion/SBR method in this application.
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There are several differences between stage I and stage III NSCLC that could be
obstacles to full clinical use. First, stage III NSCLC tumors are larger and often display
heterogeneous uptake on PET. As we saw in patient 2, this could cause problems for the
volume/motion/SBR algorithm, which was not developed with heterogeneous tumors.
Second, larger tumors are often adjacent to different kinds of tissue, which makes the
selection of “background” for the segmentation algorithm tricky. The background ROI for
patient 3 is a good example; placing the ROI in the chest wall gave a better threshold value
than placing the ROI in the lung. Third, and probably most importantly, stage III NSCLC by
definition has nodal involvement. Mediastinal and hilar lymph nodes have been shown to
move substantially with respiratory motion (Donnelly et al., 2007; Pantarotto et al., 2009;
Sher et al., 2007) and therefore could benefit from the volume/motion/SBR model, but we
have not validated the model for this application. Furthermore, GTVs for stage III NSCLC
often encompass large regions of the mediastinum if multiple nodes are present. A
localized threshold-based segmentation technique such as the volume/motion/SBR model
may be inappropriate for such an application.

5.6

Conclusions
Applying the volume/motion/SBR model to stage III NSCLC may be feasible, but

further study into the appropriateness of the application and effectiveness of the model
must be performed.
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Chapter 6 DISCUSSION

6.1

Significance and Impact
Radiation therapy is becoming increasingly important for NSCLC. SBRT has been

shown to be as effective as resection for inoperable stage I NSCLC (Chang et al., 2007;
Timmerman et al., 2007). Retrospective studies have shown promising results for the use of
SBRT in operable stage I NSCLC (Onishi et al., 2007) and investigations are currently
underway to prospectively evaluate SBRT in operable stage I NSCLC (including a multicenter
clinical trial led by M. D. Anderson.) Chemoradiation substantially benefits patients with
stage III NSCLC (Govindan, 2003).
Considering the high dose gradients associated with IMRT and high biologically
equivalent doses in SBRT, imaging is becoming ever more critical for target definition of lung
tumors. One of the more recent technologies for imaging lung cancer is 4D-CT, which can
capture the motion of the tumor during the patient’s respiratory cycle. This information
can be used to define a “motion envelope” of the tumor, what M. D. Anderson has dubbed
the “internal gross tumor volume” or IGTV. Implementation of 4D-CT, however, can be
costly and we have developed a simpler, more cost-effective alternative which provides
significant motion information by generating MIP and RACT, image sets commonly used in
target delineation, directly from cine CT. The purpose of this dissertation was to investigate
the feasibility of using these image sets in conjunction with PET imaging to define IGTV on
tumors of varying complexity.
We began in Chapter 2 by examining small, mobile stage I NSCLC tumors. We
considered 2 groups of tumors: “High-contrast” tumors located in the middle of the lung
parenchyma and “low-contrast” tumors adjacent to structures of equal or greater density.
The average volume ratios for high-contrast and low-contrast tumors were 1.05±0.14 and
0.97±0.13 respectively. It was therefore shown that IGTVs contoured with MIPcine and
RACTcine are similar to or slightly larger than IGTVs contoured with 4D-CT (Riegel et al.,
2009). In both phantom and patient studies, we found that MIPcine captured the maximum
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extent of motion more effectively than MIP4D-CT. In Chapter 3, we turned to calculation of
dose, another important aspect of treatment planning. Because RACTcine utilizes all the
images in the cine CT image sequence, there is the possibility of weighting the average
towards one phase of the breathing cycle. By calculating dose on RACT image sets formed
by averaging 1, 1.5, and 2 breathing cycles, we showed that discrepancies between dose
distributions calculated on RACTcine and RACT4D-CT were minimal (71 of 73 patients had all
points within the PTV pass 2%/1mm γ index criteria). Including more breathing cycles
reduced discrepancies even further (Riegel et al., 2008). Once dose calculation with
RACTcine and stage I NSCLC contouring with MIPcine and RACTcine were shown to be feasible
alternatives to 4D-CT, we tackled tumor contouring using PET in the hopes that it would
provide sufficient motion-inclusive targeting information to use with MIPcine and RACTcine for
more complex tumors, such as stage III NSCLC which have been shown to cause difficulties
in MIP contouring (Muirhead et al., 2008). A threshold-based segmentation model was
developed in Chapter 4 using an extensive series of phantom scans at varying sphere
volume, motion amplitude, and SBR (Riegel et al., 2010). This model was applied to 24 lung
tumors and performed better than 6 commonly-used segmentation methods at defining
IGTV (-5.15% volume underestimation compared with CT), though the difference was only
significant when compared with “first order” methods (simple thresholds of ACmax or SUV).
Finally, we combined the cine CT contouring technique from Chapter 2 with the
segmentation model from Chapter 4 to assess the feasibility of using structural and
functional image modalities together to contour tumor on stage III NSCLC and a complex
stage I NSCLC in Chapter 5. The results were mixed in that the volume/motion/SBR model
was applicable and effective in some patients but not in all. With further research, the
integration of cine CT and PET could prove to be a useful tool for physicists and radiation
oncologists to accurately define motion-inclusive target volumes for lung tumors.
Though much work remains before clinical implementation, it is worthwhile to
consider how a “cine PET/CT” simulation could be implemented in the clinic. The typical
workflow for CT simulation begins at the scanner and ends at the treatment planning
workstation. At M. D. Anderson, several pieces of hardware and software are utilized to
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perform PET/CT and 4D-CT in the same imaging session: A PET/CT scanner, respiratory
surrogate, respiratory surrogate computer and accompanying tracking software, a picture
archiving and communication system (PACS) workstation (Advantage Window [AW],
General Electric Medical Systems, Waukesha, WI), and 4D-CT sorting software (Advantage
4-D, General Electric Medical Systems, Waukesha, WI). At M. D. Anderson, 4D-CT images
are generated on the AW workstation and transferred directly to treatment planning
servers (they are not interpreted diagnostically). PET images are interpreted diagnostically
by nuclear medicine physicians and, due to the inability to interactively view PET/CT
imaging on our institution-wide PACS system, physicians utilize the AW as a “mini-PACS” to
interpret PET images. They are then sent to the treatment planning servers for planning.
To perform PET/CT and cine CT, only two pieces of hardware are required: A PET/CT
scanner and a personal computer networked to the scanner console. The only additional
piece of software required is the relatively simple code to process cine CT image sets, which
can be implemented on a standard Windows-based personal computer. If one is only
concerned with using imaging for radiation therapy treatment planning (and not diagnostic
value), 4D-CT and PET images can be sent directly to treatment planning servers, bypassing
the need for a mini-PACS (though some digital storage back-up mechanism obviously must
be in place). If the patient has not received a diagnostic PET/CT scan, however, it is
beneficial to use the PET for staging purposes due to the ability to detect distant metastasis
and the potential to change treatment intent from curative to palliative (Brink et al., 2004;
Ciernik et al., 2003; Dizendorf et al., 2003; Mah et al., 2002). The different workflows are
shown diagrammatically in Figure 6.1.
Three imaging exams should be performed in the treatment position (flat table top,
wing-board to support arms above the head, etc.) in order to gain adequate information for
treatment planning: (1) Cine CT of the thoracic cavity near the tumor using a long cine
duration (approximately 2 average breathing cycles) to maximize respiratory waveform
sampling for MIPcine (Riegel et al., 2009) and minimize weighting for RACTcine (Riegel et al.,
2008), (2) PET from base of skull to mid-thigh, and (3) free-breathing helical CT from the
skull to the knees. Cine CT is acquired to produce MIPcine and RACTcine, which are used for
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contouring purposes in high-contrast regions and motion measurement for the
volume/motion/SBR model. RACTcine is additionally used for dose calculation and, together
with the free-breathing helical CT, PET attenuation correction (Pan et al., 2006). PET is used
to assess distant metastasis and is utilized for contouring with the volume/motion/SBR
model (SBR is measured on the PET scan). Though helical CT of moving tumors does
produce artifacts, it could be used to roughly estimate tumor volume for the
volume/motion/SBR model input. The robustness of the model with respect to this input
should be studied further.
One counterargument to cine PET/CT as a cost-saving measure compared with 4DCT is the expense of the PET scan itself, both in the cost of the PET/CT scanner and FDG for
each patient. Any costs cut by excluding 4D-CT, the argument goes, would be offset by
costs of the PET scan. While it is true that the cost of PET scanning is by no means trivial,
the utility of PET imaging versus 4D-CT imaging is greater. Currently, the use of 4D-CT is
restricted to treatment planning and, in some limited cases, assessment of ventilation
(Guerrero et al., 2006). PET, however, has significant utility in diagnosis in addition to
applications in radiation oncology. It is feasible that the cooperative purchase of a PET/CT
scanner shared by departments of radiology, nuclear medicine, and radiation oncology
could defray the costs, making the cost of cine PET/CT to the radiation oncology
department manageable. Diagnostic scans could increase patient throughput on the
machine and help recoup costs.
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Figure 6.1: Workflow for (top) 4D-CT and PET acquisition versus (bottom) cine CT and PET
acquisition.
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6.2

Future Work

6.2.1 Weighted Maximum Intensity Projection (wMIP)
One of the findings of Chapter 2 was that some tumors near the diaphragm
demonstrated substantial IGTV differences when contouring with MIPcine and RACTcine. This
was mostly caused by the motion of the liver obscuring the inferior extent of the tumor’s
motion envelope. We developed an image processing technique called “weighted MIP” to
solve this problem. Essentially, the weighted MIP or “wMIP” is formed by taking the MIP of
a subset of images from the cine CT image sequence at the lung/liver junction. These
images can be processed to include images of the tumor but exclude images of the liver,
thereby discarding images that would overwrite inferior motion extent of the tumor.
Future work with wMIP will consist of contouring lesions that would otherwise be
difficult to contour with cine CT alone and automating the image selection process.
Automation could be achieved by using the liver itself as a respiratory surrogate. Since we
are only concerned with the images at the lung/liver interface (which, of course, moves
during the respiratory cycle), we could segment the lung at each slice in this region using a
CT number threshold and derive a respiratory trace by measuring the changing lung area
over the temporal cine CT sequence. Increasing and decreasing lung area would indicate
end inspiration (no liver in slice) and expiration (liver in slice) respectively.
6.2.2 Improvement in PET Uptake Quantification
An interesting byproduct of Chapter 4 was the development of the recovery
coefficient (RC) to correct for partial volume averaging and motion blur of the PET image.
Though RCs based on object size have been explored, few publications of size- and motionbased RCs exist (Park et al., 2008).
Though the function used to model the RC fit the data well overall, there were
regions of inaccuracy. Further research, including validation with gated 4D-PET/CT as the
gold standard, is warranted.
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In diagnostic PET for NSCLC, the commonly-accepted SUV for malignancy is 2.5 g/mL
(Patz et al., 1993). This value, however, was determined by correlating SUV (without any
size or motion correction) with histological results. For large, stationary tumors, SUV was
likely not affected. For small, mobile tumors, however, SUV would have been
underestimated. This may have caused dispersion in the data, clouding the relationship
between SUV and histology. It may be worthwhile, therefore, to update the study using
current technology. We intend to retrospectively recruit a large number of lung cancer
patients who have received PET and 4D-CT, measure the motion and size via 4D-CT, apply a
size- and motion-dependent RC to correct for partial volume averaging and motion blur,
and compare corrected SUVs with histology to determine an appropriate benign/malignant
SUV threshold.
6.2.3 Fine-Tuning the Volume/Motion/SBR Model
The volume/motion/SBR model is far from perfect for all the reasons listed in
section 4.5. Ultimately, we hope to use this model in situations where CT cannot
adequately define tumor boundaries, such as the stage III patients in the feasibility study
described in Chapter 5. In order to do that, the model must be robust enough to work
under a variety of conditions. Investigating asymmetry of the breathing cycle, irregular
tumor geometry, the effect of heterogeneous uptake, and improvements to the recovery
coefficient model are a few of several avenues to pursue to further refine the segmentation
model for this purpose.
6.2.4 Nodal Involvement in Stage III Non-Small Cell Lung Cancer
Perhaps the biggest difference between stage I and stage III NSCLC is the presence of
regional lymph node metastasis. As briefly discussed in Chapter 5, it is worthwhile to
consider the appropriateness of using a localized threshold-based segmentation technique
for contouring mobile hilar and mediastinal lymph nodes. Regardless of whether or not the
volume/motion/SBR model is used, the efficacy of PET in contouring nodal involvement in
conjunction with MIPcine and RACTcine should be evaluated by comparing with 4D-CT. We
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should, in essence, repeat the experimental setup detailed in Chapter 2, this time
comparing IGTVs delineated on MIPcine + RACTcine + PET versus IGTVs delineated on MIP4D-CT
+ 4D-CT phases + PET. In addition to intraobserver variation, interobserver variation should
be assessed.
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Chapter 7 CONCLUSIONS AND RECOMMENDATIONS
The results of this work are promising. We have shown that RACTcine is a viable
alternative to RACT4D-CT for the purposes of dose calculation and can be implemented
reasonably. We have shown MIPcine and RACTcine can be used to contour moving stage I
NSCLC located in the lung parenchyma and we have presented evidence that PET (via the
segmentation model) can be used in conjunction with MIP and RACT to contour smaller
tumors adjacent to structures of equal or greater density. Though more research is
required to assess the efficacy of PET in stage III disease, the work presented here provides
a solid foundation for future investigations.
The cine PET/CT workflow in Figure 6.1 reduces the complexity of the motioninclusive simulation process and could substantially reduce the costs of motion-inclusive
imaging for radiation therapy simulation. Though more research is required to fine-tune
the technique, we have 4 recommendations:
•

If 4D-CT is not available, we recommend acquiring cine CT and free-breathing helical
CT for treatment simulation of lung cancer patients, including the use of MIPcine and
RACTcine for contouring and RACTcine for dose calculation. Any motion information is
better than none.

•

If 4D-CT is available, we recommend that MIPcine be used with phase imaging
because it more accurately captures the maximum motion extent of the tumor than
MIP4D-CT. Dose calculation with either RACT4D-CT or RACTcine is recommended.

•

If PET/CT is available, we recommend that IGTV be contoured primarily on CT (cine
CT or 4D-CT) using volume/motion/SBR model as a supplemental guide when
contouring small, mobile tumors with relatively homogenous uptake on PET.
Further research is required to recommend use in larger, more complex lesions.

•

If cine CT is acquired, we recommend that cine duration be set as long as possible (2
average breathing cycles is a good target) to maximize sampling of the respiratory
waveform and minimize density weighting effects.
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Chapter 8 APPENDIX
A detailed description of the surface separation algorithm is provided here. The
code is basically split into two main parts: First, the “reference” surface mesh is sampled by
calculating the intersection of equally-spaced vectors projected from the center of the
reference ROI and the triangular mesh surface; second, the shortest distance between the
sampling point on the reference mesh and the test mesh surface is calculated.

8.1

Sampling the Reference Surface
The centroid (the center of mass assuming unit density) of the reference ROI is

determined by averaging the pixel coordinates inside the ROI. Vertices of the reference
mesh are transformed such that the reference ROI centroid is the origin of the coordinate
system. Rays are projected from the origin (the centroid) at regular azimuthal and
altitudinal angles. For our study, we used an angular interval of 5°.
The mesh surface is made of hundreds or thousands of adjacent triangles which
connect the vertices of the mesh. Each triangle defines a plane. Our task is twofold: We
must calculate the intersection of the sampling vector with the plane and also determine
whether or not the intersection is inside the triangle defined with the mesh vertices.
Furthermore, we must iterate this process for all triangles, for every sampling ray.
Mathematically, if we consider r1, r2, and r3 to be vertices of a triangle on the
reference surface mesh, the plane that contains the triangle is defined by equation ( 14 ):
st, u

6- ? 68889 n 8889
8889
6- t ? 68889b n 8889
6- u

( 14 )

where u and v are barycentric coordinates of a point in the plane of the triangle (Moller et

al., 1997). The equation for the ray originating from the reference centroid (denoted by v,

the origin of the coordinate system) is:
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Sw

89 n v9 zw
v9 ? xℓ

( 15 )

where 89
ℓ is the directional ray vector and t is the length of the ray (in this case, a parametric
variable).

According to Moller and Trumbore (Moller et al., 1997), we can simultaneously
determine the intersection of the ray with the plane and whether or not the intersection is
inside the triangle by setting equation ( 14 ) equal to equation ( 15 ) and solving for the
vector [t u v].
89 n v9 zw
v9 ? xℓ

6- ? 68889 n 8889
8889
6- t ? 68889b n 8889
6- u

( 16 )

By rearranging and putting this equation into matrix form,
v% n 6-,%
{v| n 6-,| ~
v} n 6-,}

v% n ℓ%
{v| n ℓ|
v} n ℓ}

6 ,% n 6-,%
6 ,| n 6-,|
6 ,} n 6-,}

6b,% n 6-,% w
6b,| n 6-,| ~ t
6b,} n 6-,} u

( 17 )

we can take the inverse of the middle matrix to determine [t u v].
w
t
u

v% n ℓ%
{v| n ℓ|
v} n ℓ}

6 ,% n 6-,%
6 ,| n 6-,|
6 ,} n 6-,}

6b,% n 6-,% +- v% n 6-,%
6b,| n 6-,| ~ {v| n 6-,| ~
v} n 6-,}
6b,} n 6-,}

( 18 )

Because u and v represent barycentric coordinates, they are relative to the vertices
of the triangle. Therefore, if the solution of u and v satisfies the following conditions,
0t1
0u1
t?u 1
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then the intersection of the ray and the plane lies within the triangle defined by r1, r2, and
r3, and the coordinates of the intersection can be found by plugging the solution for t into
equation ( 15 ). The intersection coordinates are deposited into a new matrix of points that
“sample” the reference mesh surface. If the point lies outside the triangle, it is discarded.
This is repeated for all triangles and all sampling rays.
For typical convex shapes, the number of sampling points will equal the number of
sampling rays. There are clinical scenarios, however, when the tumor contains spiculations
and will cause multiple intersections of the ray with the mesh surface. The algorithm is
designed to include these multiple intersections in the surface separation calculation.

8.2

Determination of Shortest Distance between Reference and Test Surfaces
First, the test surface mesh is transformed to the reference ROI centroid coordinate

system. The next step is to measure the separation between the reference surface and the
test surface by calculating the shortest distance from each sampling point to the test
surface. There are two outcomes: Either the shortest distance is on a face of the surface
mesh (inside the triangle formed by the vertices) or it is on the edge of the surface mesh
(one of the lines connecting the vertices). The algorithm is designed to consider each
scenario separately and determine which distance is smaller.
8.2.1 Faces
First, to measure the distance from the sampling point to each plane formed by the
surface triangles, we must calculate the projection of the sampling point q on every plane.
To do so, we must establish orthogonal basis vectors within each plane using the GramSchmidt process (Lay, 1997). To summarize, if p1, p2, and p3 are vertices of a triangle on the
test surface mesh and q is the point to be projected onto that plane, consider the vectors
!8889


88889 n 
8889,
88889
- !


88889b n 
8889- , and Z9

equations ( 19 ) and ( 20 ):

9 n 8889.
- Orthogonal basis vectors are formed using
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u88889

u
88889

!8889

( 19 )

 
88889 n 88889·
!
u
88889
88889 -

88889·
% 88889


( 20 )



The projection of the sampling point onto a p-dimensional space is defined by Lay (Lay,
1997):

Z

89·
888889
|


t ?  ? 888889·888889 88889
88889
t
888889·
888889 89·
888889
|


 

 

( 21 )

Where t- ,  , t  is an orthogonal basis of the plane. In our case, the orthogonal basis is
provided by the Gram-Schmidt process, and the projection is demonstrated in equation
( 22 ):

Z


u
88889
?
u
88889 ? 88889
88889·88889
88889·88889

89·88889
|





89·88889
|


( 22 )



We now have two points that define a line normal to the plane: q, the sampling point on

the reference mesh, and Z, the projection of q on the plane. Using the method described in

the previous section, we determine whether or not this line falls inside the vertices of the
plane-defining triangle p1, p2, and p3. If Z lies within the triangle, the distance Z n  is

placed in a matrix where “candidate” shortest distances are stored. If it lies outside the
triangle, it is discarded.
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8.2.2 Edges
The sampling point is then projected on each edge of the triangle using equation

( 21 ) with only 1 basis vector for each edge. The edges are defined thusly: 88889
u-

88889
u
88889
Z


88889b n 
8889,
ub
- 88889


88889b n 
88889. The vectors to be projected are defined as such: 88889
Z-

9 n 88889
 ). The projections are therefore:

Z
-

Z

Z
b

u88889
88889·
 88889


88889·
| 88889


88889·
| 88889

88889·
 88889


88889·
| 88889

88889·
 88889



88889 n 
8889,
-

9 n 8889,
-

? 88889
-

u
88889 ? 88889
-

( 23 )

u
88889b ? 
88889

The distances from the sampling point q to each projection is stored in the
“candidate” matrix, along with the distance from q to the triangle face (if the normal lies
inside the triangle). This represents one iteration of the process. The process is repeated
for all triangles and the shortest distance of all the triangles is recorded as the surface
separation for that particular sampling point. The process is iterated over all sampling
points. A visualization of the surface separation algorithm is shown in Figure 8.1.
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Figure 8.1:: End result of the surface separation algorithm. Black mesh is "reference"
mesh. Red mesh is "test" mesh. Blue lines represent shortest distances from the
sampling points on the reference mesh to the test mesh surface.
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